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ABSTRACT
The Effects of Transcutaneous Electrical Neurostimulation on Analgesia and Peripheral
Perfusion
Leah Schafer
Peripheral arterial occlusive disease (PAOD) affects 8 to 12 million Americans
over the age of 50. As the disease progresses, arterial occlusions arising from
atherosclerotic lesions inhibit normal metabolic vasodilation in the peripheries, resulting
in limb ischemia and claudication. Pharmacological and surgical treatments currently
used to treat both the hemodynamic and pain symptoms associated with PAOD can
involve adverse and potentially life-threatening side effects. Thus, there is a need for
additional innovative therapies for PAOD.
Neurostimulation has a known analgesic effect on both acute and chronic pain.
Although the exact mechanisms remain under investigation, local vascular tone may be
modulated by neurostimulation in addition to pain modulation. The Gate Control Theory
proposes that electrical activation of mechanoreceptive afferent somatosensory nerves,
specifically Aβ fibers, inhibits pain signaling to the brain by activating an inhibitory
interneuron in the dorsal horn of the spinal cord which dampens signaling from afferent,
C type peripheral nociceptor nerves. Interestingly, Aβ fiber activation may also inhibit
norepinephrine release from sympathetic nerve terminals on efferent neurons by
activating α-2 adrenergic receptors along the same dermatome, resulting in localized
vasodilation in both limbs. Ultimately, electrical stimulation may decrease mean blood
pressure and increase local blood flow.
The focus of this study was to optimize protocols and perform a small scale
clinical study to investigate hemodynamic and analgesic responses to neurostimulation
during acute ischemia. We hypothesized that ganglial transcutaneous electrical
neurostimulation (TENS) and interferential current (IFC) treatments would decrease pain
perception and vascular resistance in the periphery in young, healthy subjects. We further
hypothesized that IFC may have a greater hyperemic and analgesic effect on acute
ischemia than TENS as its current waveform may be more efficient at overcoming skin
impedance. Interestingly, we found trends suggesting that TENS and IFC may increase
vascular resistance (VR) and have no noticeable analgesic effect, though TENS may have
a slightly lower increase in VR associated with an increase in pain. Further work
characterizing the hemodynamic effects of different stimulus waveforms is needed to
inform future research into possible neuromodulation therapies for ischemic disease.
Keywords: Neurostimulation, ischemia, blood flow, hyperemia, vascular resistance,
analgesia, peripheral artery occlusive disease
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CHAPTER 1: INTRODUCTION

1.1 PERIPHERAL ARTERY OCCLUSIVE DISEASE
1.1.1 Prevalence and Etiology
Peripheral arterial occlusive disease (PAOD) affects 10% of the American
population, rising to 20% in persons over 70 years of age [1]. PAOD is more prevalent in
men than in women, though non-fatal events are more frequent in women with PAOD
than men [2]. Risk factors associated with PAOD also include diabetes, smoking,
hypertension, and dyslipidemia [3], Figure 1.1.

Figure 1.1: Risk Factors for PAOD. Gender, age, smoking, and diabetes effect the risk
of developing PAOD [3]. Males have 10-20% greater risk than females. Increased age
raises risk by 20-30% for each 10 year age bracket. Diabetes and smoking increase risk
by 30-40%, while hypertension and dyslipidemia increase risk by 10-20%.

PAOD is caused by atherosclerosis that leads to arterial stenosis in peripheral
conduit arteries, Figure 1.2. Although resting blood flow in PAOD patients is similar to
1

that in a healthy person, arterial occlusions inhibit metabolic vasodilation in the
peripheries, resulting in limb ischemia [4]. Once metabolic demands rise above tissue
perfusion levels, muscle fatigue and acute ischemic pain result. The pain, also known as
intermittent claudication (IC), and fatigue often subside after the cessation of muscle
contraction and a return to resting metabolic demand. Although symptomatic stabilization
may occur due to the development of collaterals, pain and fatigue can become chronic as
arterial stenosis progresses [3].

Figure 1.2: Atherosclerotic Arterial Stenosis: The narrowing and hardening of
peripheral arteries in PAOD causes decreased blood flow and vascular tone [5].

1.1.2 Diagnosis
When claudication and fatigue symptoms occur, several tests are used to screen
for PAOD. For artery disease in the legs, the most widely used test is the ankle-brachial
systolic pressure index (ABI) which compares ankle blood pressure to arm pressure at
rest. A resting ABI of ≤0.90 used as a hemodynamic definition of leg PAOD [6]. A
2

similar comparative blood pressure reading is used for PAOD screening in the arms,
where a reduced blood pressure in one arm as compared to the other, as well as reduced
pressure distal to the suspected blockage, is indicative of peripheral arterial stenosis.
Diagnosing PAOD in asymptomatic patients requires advance screening. For this
reason, coronary artery disease (CAD) can be indicative of PAOD in asymptomatic
patients as PAOD and CAD are both manifestations of atherosclerosis. In the primary
care setting, approximately half of patients diagnosed with PAOD also have CAD, and
PAOD patients are at a higher risk for heart attacks and strokes [3]. Other hemodynamic
imaging studies used to diagnose or characterize PAOD include Doppler ultrasound,
magnetic resonance angiogram (MRA), and x-ray arteriogram.
1.1.3 Current Treatment Options
Following diagnosis, current treatment options for PAOD include lifestyle
changes, pharmacologic interventions, and/or surgery. Diet modification is directed
toward lowering low density lipoprotein (LDL) consumption, as LDL cholesterol plays a
major role in endothelial activation associated with atherosclerotic plaque formation [7].
Increasing exercise and smoking cessation are also important lifestyle changes known to
decrease LDL concentration and improve overall cardiovascular health [8]. However, diet
and exercise alone are often not sufficient to achieve recommended lipid levels;
therefore, pharmacological treatments are often necessary.
Statins are prescribed to lower LDL cholesterol levels in PAOD patients and are
associated with a 20% reduction in major adverse cardiovascular events such as
myocardial infarction and stroke [9, 10]. Furthermore, the antiinflammatory,
antiproliferative, and antithrombogenic properties of statins improve claudication and
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atherosclerosis associated with PAOD [11]. Antihypertensive drugs such as diuretics, βadrenergic inhibitors (e.g. β-blockers), angiotensin-converting-enzyme (ACE)
inhibitors/angiotensin receptor blockers, and calcium channel blockers are also
commonly prescribed to reduce blood pressure (BP), which in turn slows the progression
of atherosclerosis by reducing shear and oxidative stress in the blood vessel lumens.
Thiazide diuretics are safe and effective for reducing BP in the general patient
population, while ACE inhibitors are often used in patients with diabetic renal disease or
congestive heart failure [12]. Calcium channel blockers are used in cases in which
hypertension is more difficult to control, while adrenergic inhibitors are selectively used
for cardioprotection in PAOD patients who also have concomitant coronary disease [3].
If drug therapies are insufficient, surgical intervention is also used to improve
blood flow in PAOD patients. Percutaneous transluminal angioplasty (PTA) is a
minimally invasive procedure used to compress atherosclerotic plaque inside the arterial
wall, Figure 1.3. Long-term success rates for aortoiliac and femoropopliteal PTA are
between 50-70% after 5 years [13]. However, hyperplasic restenosis due to a combination
of localized inflammation, atherosclerosis, thrombosis, scar tissue formation, and
proliferation [14, 15] occurs in up to 25–30% of PAOD patients and is a major problem
limiting its long-term efficiency [11, 16]. Thus, angioplasty is often followed by stenting
to preserve the structure of the vessel wall and reduce restenosis.
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Figure 1.3: Percutaneous Angioplasty and Stenting. A. Intravascular deflated balloon
catheter guidewire inserted into stenosed region. B. Non-stented balloon inflated; plaque
compressed against arterial wall. C. Stented balloon inflated; plaque compressed and
stent expanded. D. Stent preserves vessel shape and delays restenosis [17].

Other intervention options for PAOD include atherectomy and bypass grafting.
Rather than being compressed, plaque is removed by cutting, pulverizing, and shaving
via a catheterized endarterectomy device. Although initial success is greater than PTA,
restenosis and patency constraints occur in almost half of the patients at 12 months postatherectomy [18]. Arterial bypass grafting is a more invasive surgical intervention used
as a last line of treatment for cases in which pharmacological or percutaneous
interventions are not effective. This procedure involves redirecting blood flow around the
stenosed section by attaching a healthy autologous or synthetic blood vessel at either end

5

of the blockage, Figure 1.4. However, over the past 20 years, the use of bypass surgery
to treat PAOD has decreased by 42% in clinical settings [19].

Figure 1.4: Arterial Bypass Graft. Blood flow is redirected around the stenosed region
by grafting a new vessel around the blockage [20].

Cell-based therapies for PAOD are currently under investigation. An ongoing
Stage 3 trial is investigating the safety and efficacy of autologous bone marrow aspirate
concentrate (BMAC) for treating critical limb ischemia due to peripheral arterial disease
[21]. It is postulated that intramuscular injections of BMAC into ischemic tissues will
result in improved angiogenesis and blood flow. If successful, this treatment could
improve blood flow and reduce ischemic pain.
Although treatment options do exist for PAOD and its symptoms, long-term
efficacy is limited. Lifestyle changes may slow the progression of the disease, but may
not be sufficient for disease management. Pharmacological and surgical complications
are also prevalent. Statins impair memory, damage the liver, and raise blood sugar [22],
while diuretics and beta-blockers may also cause insulin resistance [23]. Angioplasty and
stenting have high restenosis rates and increase the thrombogenicity of the vessel wall,
6

while arterial grafts are very invasive and expensive and have a higher risk of major
adverse cardiac events [24]. To more safely and effectively address PAOD and its
symptoms, additional approaches are needed. Electrical stimulation is one such
alternative to drug treatments for painful conditions and possibly ischemia.

1.2 NEUROSTIMULATION
1.2.1 Modalities and Functions
Several modalities of neurostimulation exist, including transcutaneous stimulation
such as TENS and interferential current (IFC) as well as implanted technologies such as
spinal cord stimulation (SCS) and deep brain stimulation. Implanted devices tend to be
more effective at alleviating pain but carry a risk of device failure or surgical
complication and are therefore reserved for more severe cases, while transcutaneous
modalities have been proven to be safe and effective for the general patient population
with more moderate pain and are available both clinically and commercially [25].
Both implanted and transcutaneous forms of neurostimulation have a known
analgesic effect on patients suffering from acute [26, 27, 28] and chronic [29, 30, 31]
pain, and on healthy subjects in whom acute pain has been induced experimentally [32,
33, 34, 35]. Although clinical and experimental pain are not directly comparable,
experimental pain is used to investigate pain pathophysiology and to evaluate analgesic
effects under controlled conditions [36]. The onset and duration of analgesia may vary
considerably between patients [37], and the same protocol may have different degrees of
antinociception in acute experimental pain compared with chronic clinical pain [38].
Neurostimulation may also have a hyperemic effect [32, 39]. While the exact molecular
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pathways for how neurostimulation achieves these effects remain under investigation,
there is likely more than one mechanism of action.
1.2.2 Mechanisms of Action
1.2.2.1 Modulating Pain: Gate Control Theory and Endogenous Signaling
The most prevalent model for electrically-induced analgesia is the gate control
theory (GCT). The GCT postulates that analgesia is achieved by electrical activation of
afferent Aβ (large, cutaneous, myelinated) fibers which synapse onto ascending neurons
in the central nervous system (CNS) on the same level as afferent C (small, cutaneous,
unmyelinated) nociceptive fibers, Figure 1.5. Nociceptive signals traveling through C
fibers from peripheral nociceptors activate second-order neurons in the substantia
gelatinosa on dorsal horns along the spinothalamic tract (STT). STT neurons are
responsible for carrying the signal to the thalamus for pain cognition.
Neuropeptide substance P is involved with modulating ascending nociceptive
information in the STT, as is nitric oxide (NO). NO activates a guanyl cyclase protein
signaling cascade, which in turn elevates intracellular cyclic guanosine monophosphate
(cGMP) levels, further activating a protein kinase G cascade and ultimately amplifying
the pain signal in the STT neuron. NO may also react with superoxide and increase
central pain sensitization and hyperalgesia [40].
When an electrical stimulus is applied, mechanoreceptive Aβ neurons are
activated and accompanied by a localized tingling, “buzzing” sensation known as
paresthesia. As Aβ signaling increases, the ratio of large-fiber to small-fiber activity
increases, activating an inhibitory interneuron synapsing to the ascending ST neuron and
ultimately weakening the pain signal to the brain [41].
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Figure 1.5: Gate Control Theory for Modulating Pain. A. Unmodulated (normal)
pain: Peripheral pain signals travel up afferent C fibers to the CNS where they stimulate a
second-order ST neuron and inhibit suppression by the inhibitory interneuron. B.
Modulated pain: Neurostimulation stimulates afferent Aβ fibers parallel to afferent pain
fibers in the CNS, resulting in the activation of an inhibitory interneuron and a
suppressed pain signal to the thalamus [42].

Simultaneous to the reduction in pain sensation, the effect of the metaboreflex
may be reduced. Normally, the metaboreflex is triggered by ischemic by-products such as
adenosine and potassium which stimulate intramuscular chemoreceptors that send signals
to type C fibers. Inhibition of type C small-fiber afferent signals by simultaneous Aβ
activation would decrease the strength of the metaboreflex, resulting in a systemic
decrease in vascular resistance [43]. Interestingly, the vasodilatory effect of
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neurostimulation is likely stronger in PAOD patients than in healthy individuals. PAOD
increases sympathetic activation as evidenced by increased concentrations of ischemic
by-products and mean blood pressure (MBP) in response to exercise [44].
Endogenous opiate release may also be effected by neurostimulation. Β-endorphin
levels increase in the lumbar cerebrospinal fluid (CSF) with low-frequency stimuli,
resulting in an antinociceptive effect [45]. These effects were reversed by naloxone,
indicating that low-frequency analgesia is mediated by micro-opioid receptor activity
[46]. Interestingly, high-frequency TENS results in increased dynorphin A levels in the
CSF with analgesic effects that are not reversed by naloxone, implicating dynorphinbinding receptor activity [45]. These results indicate a frequency-dependent endogenous
response to neurostimulation.
1.2.2.2 Modulating Blood Flow and Ischemic Pain: α-2A Receptor Activation
It is also postulated that neurostimulation increases blood flow and decreases pain
in the periphery via a second Aβ fiber pathway. Although the mechanism is unclear,
ganglial stimulation of Aβ fibers initiates an efferent action potential that propagates
down to α-2 adrenergic receptors (α-2A-Rs) in vascular sympathetic neuron terminals.
These receptors are responsible for presynaptic inhibition of smooth muscle contraction
by inhibiting norepinephrine (NE) release from sympathetic nerve terminals, Figure 1.6.
α-2A-Rs are coupled to N-type calcium (Ca2+) channels in SNS neuron terminals, and
activation reduces Ca2+ influx and subsequently decreased SNARE complex activity.
Less norepinephrine (NE) is released into the synaptic cleft, and the interrupted
sympathetic neuron signaling decreases vasoconstriction in the affected tissues and
ultimately increases blood flow and reduces ischemic pain [47].
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Figure 1.6: α-2A Receptor Activation. Activation of α-2 adrenergic receptors causes
presynaptic inhibition of signal transmission due to suppressed neurotransmitter (i.e.
norepinephrine, NE) release [47].

Interestingly, neurostimulation may have a time-sensitive effect that does not
immediately present but extends beyond the period of stimulation itself, termed the
“carry-over” effect. Evidence suggests that while TENS does not improve time to onset
of ischemic pain, pre-treatment with TENS increases local blood flow and improves
exercise tolerance at later time points [48]. Although the mechanism is unclear, it is
possible that the carry-over effect may be associated with latencies in cellular activation.
In the context of PAOD, increased blood flow to ischemic peripheral tissues
resulting from α-2A receptor activation would also reduce ischemic pain. In this way,
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neurostimulation may have an additive analgesic effect in occluded tissues by
simultaneously closing the pain gate and alleviating peripheral ischemia, Figure 1.7.
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Figure 1.7: Effects of Neurostimulation on Pain and Blood Flow. Stimulation of Aβ
fibers has two effects: closing the pain gate in the central afferent pathway and activating
α-2A receptors in the peripheral efferent pathway. Both pathways result in decreased pain
and sympathetic control and ultimately increased blood flow.
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1.2.3 Justification for the Use of TENS and IFC
A combination TENS/IFC transcutaneous neurostimulation device was chosen for
the study because of its low cost and non-invasiveness, though the methodologies for
investigating changes in peripheral perfusion associated with neurostimulation proposed
by our study may translate to future research associated with implantable technology such
as SCS. To our knowledge, there have been no previous studies directly comparing the
hemodynamic effects of TENS and IFC, although studies with similar protocols have
investigated each individually [34, 49, 50, 32, 51, 52]. Although both types of stimulation
are known to effect pain and blood flow, the waveform and frequency settings have not
yet been optimized for all possible indications.
1.2.4 Waveform Characteristics
The two current waveforms most often used to study the analgesic effects of
transcutaneous neurostimulation are biphasic pulsed currents characteristic of
transcutaneous electrical nerve stimulation (TENS) and burst-modulated, sinusoidal
alternating currents characteristic of interferential current (IFC) [53, 54]. More
specifically, two out-of-phase sine waves combine to produce an IFC, Figure 1.8 [55].
These two waveforms are also used in implantable SCS therapies, with conventional SCS
utilizing a symmetric pulsatile current similar to TENS while more contemporary
therapies utilize burst-mode currents similar to IFC [56].
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A

B

Figure 1.8: TENS and IFC Stimulus Waveforms. A. Biphasic pulsed current
characteristic of conventional TENS. B. Sinusoidal burst-modulated alternating current
characteristic of IFC [29].

Since membrane properties such as voltage-gated ion channel density, input
resistance, capacitance, and synaptic contacts vary considerably between different neuron
types and substructures (e.g. C fiber vs. Aβ fiber, axon vs. soma), it is likely that a
waveform-dependent response exists [57, 58]. Conventional pulsatile current, such as in
TENS, contains broad spectral energy that may limit the ability to preferentially activate
neuronal targets, while narrow band sinusoidal waveforms, such as in IFC, may provide
greater selective control [59]. Indeed, symmetrical charge-balancing stimuli greatly
diminish selectivity in stimulating targeted neurons within the CNS, while asymmetrical
biphasic stimuli enable selective activation of cells [60]. What is more, sinusoidal IFC
waveforms may more readily overcome skin impedance and stimulate deeper Aβ fibers
than pulsed TENS and therefore have greater analgesic and hyperemic effects [49, 61,
62]. It is also possible that burst-modulated currents have a different effect than
symmetrically pulsed currents, as well as high versus low frequencies [63]. Indeed,
different endogenous signaling mechanisms occur during SCS with burst mode versus
tonic mode stimuli [56] as well as with high (100 Hz) versus low (20 Hz) stimulus
frequencies [46].
14

Although there is significant evidence that both TENS [32, 62, 64, 65, 66, 67] and
IFC [68, 69, 49] effectively reduce experimentally induced pain, there is limited research
comparing high and low frequency TENS and IFC treatments in their efficacy in
increasing blood flow. However, there is little consensus in studies attempting to
characterize changes in pain or blood flow by stimulus frequency or waveform [50].
Rather, optimal settings of stimulus parameters are subjective and are determined by trial
and error [70].
1.3 OVERVIEW AND SPECIFIC AIMS
1.3.1 Overview
Neurostimulation may offer an innovative treatment option for patients suffering
from PAOD. To date, there is no consensus on the effectiveness of different types of
neurostimulation on modulating blood flow and pain in ischemic tissues, though it is
believed that electrical stimulation decreases thalamus activity and sympathetic control of
vascular tone by activating Aβ fibers. The focus of our study is to investigate
hemodynamic and analgesic responses to transcutaneous neurostimulation during
ischemia by performing a small scale clinical study and optimizing methodologies and
protocols.
1.3.2 Specific Aims
The specific aims of this thesis are as follows:


Aim 1: Develop and optimize a protocol for investigating hemodynamic and
analgesic responses to transcutaneous neurostimulation during acute ischemia in
young, healthy Cal Poly students through exploring stimulus waveforms and
frequencies during pilot studies.
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Aim 2: Test the hypothesis that transcutaneous electrical neurostimulation
(TENS) and interferential current (IFC) treatments at the ganglia would result in
decreased pain and vascular resistance in the periphery in young, healthy subjects.



Aim 3: Test the hypothesis that IFC has a greater hyperemic and analgesic effect
on acute ischemia than TENS due to differences in stimulus current waveforms.
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CHAPTER 2: PILOT WORK

2.1 INTRODUCTION
The overall goal of the pilot work was to develop and optimize a protocol for
investigating hemodynamic and analgesic responses to transcutaneous neurostimulation
during acute ischemia in young, healthy subjects. Therefore, the goals of the first pilot
study were to ensure that our blood flow measurement instrumentation was functioning
as expected, i.e. reporting zero perfusion during occlusion and hyperemia during
recovery, and to optimize the neurostimulation frequency to elicit elevated perfusion and
decreased pain during occlusion. Endogenous pain control mechanisms may be affected
differently by high versus low stimulus frequencies [45, 46] and therefore we
hypothesized that high (100 Hz) TENS and IFC stimulation frequencies would increase
blood flow and analgesia during acute experimental pain in healthy subjects compared to
low frequencies (20 Hz).
After determining optimal instrumentation settings and neurostimulation
frequency parameters in pilot study I, pilot studies II, III, and IV tested the hypothesis
that neurostimulation has analgesic and hyperemic effects, possibly elevated with IFC as
compared to TENS due to different effects of biphasic and sinusoidal stimulus
waveforms on Aβ fibers [56]. After observing no noticeable differences in analgesic
trends associated with TENS and IFC during pilot study II, pilot studies III and IV
utilized multiple pain scales to better quantify sensations of pain experienced as a result
of arterial occlusion. The additional pain scales gave insight that neurostimulation
paresthesia was being perceived as a painful stimulus by the otherwise healthy subjects.
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For this reason, pilot study IV accounted for sensations of paresthesia by including
paresthesia descriptors in the general pain assessments. In this way, each consecutive
pilot study served to refine our hypotheses and methodologies for the main investigative
study.
All participants completed an Informed Consent form and a confidential Medical
History Questionnaire that was reviewed by the primary researcher prior to treatment.
Any contraindications for transcutaneous neurostimulation, i.e. pregnancy or history of
epilepsy, cardiovascular disease, dermatitis, syncope, or chronic pain, were grounds for
exclusion, though no participants were excluded during any pilot work. All recruitment
and experiments were performed in accordance with protocols approved by Cal Poly’s
Human Subjects Committee.
2.2 PILOT STUDY I
2.2.1 Methods
Pilot study I was performed on 12 healthy Cal Poly students aged 18 to 23 years
assigned to one of two treatment groups: TENS (n=6) and IFC (n=6). Each group
received three treatments: high frequency (100 Hz), low frequency (20 Hz), and sham (0
Hz) neurostimulation, all involving 50 µs pulses at 8 mA pulse amplitude.
Neurostimulation leads were always applied to the participant’s back regardless of
treatment to maintain a single-blinded study. The participant was never notified of the
treatment that was being applied, and all sensors and cuffs were applied in the same
manner for every treatment. Treatment order was randomized and treatments were
performed consecutively with a 10-minute rest period allotted between trials to minimize
fatigue.
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The cell bodies of Aβ fibers that innervate the arms and hands form ganglion
parallel to the 7th cervical and 4th thoracic vertebrae (C7 and T4, respectively). The
modulatory effects of TENS and IFC on pain and blood flow are substantiated when the
electrodes are placed over the C7 and T4 ganglion rather than over the active muscles of
the hand and forearm [unpublished observations]. Therefore, two pairs of
neurostimulation electrodes (InTENSity TENS/IFC Combination Stimulator, Current
Solutions LLC, Austin, TX, USA) were aligned with the C7 and T4 vertebrae on either
side of the spinal column in a quadripolar formation using re-usable carbon electrode
pads (Tyco Gel Pads, Santamedical, Tustin, CA, USA). Participants wore a loose shirt or
tank top to allow access to the upper back, Figure 2.1.

A

B

Figure 2.1: Electrode Placement. A. Topical electrodes were aligned with the C7 and
T4 vertebrae for ganglial stimulation [32]. B. Participants wore loose clothing to allow
access for electrode placement in a quadripolar formation.
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Two of the most prevalent methods for experimentally inducing pain are the
submaximal tourniquet technique and the cold pressor test, both of which cause
decreased blood flow to the effected tissues. We chose to use the tourniquet technique as
it takes effect quicker and had a more rapid reperfusion rate after releasing the occlusion
[71, 65, 68, 69], allowing for a more efficient protocol. Therefore, ischemic conditions
similar to PAOD were modeled in otherwise healthy subjects using a
submaximal tourniquet technique whereby a manual blood pressure cuff was inflated to
180 mmHg for 3 minutes on the dominant forearm. To test the hypothesis that
neurostimulation increases perfusion associated with acute ischemia, we measured
changes in local blood flow (BF) distal to the occlusion and mean arterial pressure (MBP)
on the contralateral arm.
At the start of each treatment session, participants sat in a relaxed position with
their arms resting on a tray. An automated blood pressure cuff (Omron 7 Series Wireless
Upper Arm Blood Pressure Monitor, BP761, Hoffman Estates, IL, USA) was applied to
the contralateral upper arm to measure MBP and HR every 3 minutes as specified in the
monitor’s instructions for use on timing. After attaching the electrodes to the upper back,
an optic Laser Doppler Flowmetry (LDF) skin probe (VP1 probe, Moor Instruments,
Wilmington, DE, USA) was adhered to each palm using double sided adhesive (PADs,
Moor Instruments). A hand grip dynamometer (ADInstruments, Colorado Springs, CO,
USA) was gripped in the dominant hand. The probe cables coupled to a LDF data
acquisition unit (moorVMS-LDF, Moor Instruments), which output to a PowerLab DAQ
(PowerLab, ADInstruments) and digital chart recording software (LabChart 8.0,
ADInstruments) Figure 2.2.
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The hyperemic and analgesic effects of each treatment type were evaluated during
the pressor response to static handgrip exercise at 30% maximal voluntary contraction for
3 minutes followed by a 3 minute occlusion. Change in distal blood flow and pain from
resting baseline values were evaluated before, during, and after exercise and occlusion.
This temporary circulatory occlusion in young healthy subjects was an imperfect
approximation to PAOD as chronically ischemic tissues have depleted adenosine
triphosphate (ATP) and glycogen stores, as well as elevated levels of metabolic
byproducts such as lactate, which hinder rapid reperfusion (i.e. reactive hyperemia) once
the occlusion is removed [72]. PAOD patients will also have tremendous endothelial
dysfunction as compared to healthy young subjects, hindering their vasculature’s
capability to respond to stimuli. Therefore, we would expect the reperfusion rates
observed in response to our experimentally induced ischemia to be faster than in PAOD
patients.
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Figure 2.2: Experimental Setup. A. Participants sat in a relaxed position with arms
resting on the tray in a prone position. Optic Laser Doppler Flowmetry (LDF) skin probes
(a) were adhered to each palm using double sided adhesive. A manual BP cuff (b) was
affixed to the participant’s dominant forearm to occlude the treatment hand. A hand grip
dynamometer (c) was gripped in the dominant hand. An automated BP monitor was
affixed to the upper contralateral arm (d) and the TENS/IFC unit (e) electrodes were
placed on the upper back. B. The probe cables coupled to a moorVMS-LDF data
acquisition unit (f) which connected to a PowerLab DAQ (g) via two analog inputs. The
LDF signals were transmitted to a laptop via USB cable and recorded in real time using
LabChart v.8 software.

The Numeric Rating Scale (NRS) was used to assess pain on a scale of 0 – 10
every 60 seconds, 0 being no pain and 10 being the worst pain imaginable. The maximum
pain was reported for each 60 second interval and raw hemodynamic data was averaged
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for 60 second intervals during each phase. Although both absolute change and percent
change models were run for both responses, absolute change had more statistical power
(higher R2) for analyzing this pain and blood flow dataset and therefore all results are
reported in terms of absolute change from baseline. Blood flow and pain responses were
compared to phase, ischemic conditions, and treatment type by two-way ANOVA for
repeated measures using Minitab statistical software. Post hoc comparisons were made
using Tukey-Kramer’s intervals.
2.2.2 Results
2.2.2.1 Pain
As expected, pain trended to increase during occlusion. However,
neurostimulation did not appear to have an analgesic effect as predicted; to the contrary,
pain trended to be greater with both high and low frequency TENS and IFC treatments at
each phase than the sham treatment, Figure 2.3.

*

Figure 2.3: Change in Pain for Pilot Study I. Change in pain from baseline during A.
High (100 Hz) and low (20 Hz) frequency TENS and B. High (100 Hz) and low (20 Hz)
frequency IFC (n=6). Values are shown as mean ± SE. *p≤0.05 for ∆pain vs. phase.
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2.2.2.2 Blood Flow
As expected, blood flow increased in the palm during exercise and during the
recovery phase following an acute forearm occlusion. There were no differences in blood
flow between high and low frequency TENS treatments, though perfusion was lower
during the recovery phase of the high frequency IFC treatment, Figure 2.4.

Figure 2.4: Change in Blood Flow for Pilot Study I. Change in blood flow from
baseline during A. High (100 Hz) and low (20 Hz) frequency TENS and B. High (100
Hz) and low (20 Hz) frequency IFC (n=6). Values are shown as mean ± SE. *p≤0.05 for
∆blood flow vs. phase.

2.2.3 Discussion
To test the hypothesis that high (100 Hz) TENS and IFC stimulation frequencies
increase blood flow and analgesia more so than low frequencies (20 Hz), pilot study I
compared changes in blood flow and pain elicited by both modalities before, during, and
after acute ischemia. Both TENS and IFC had a hyperalgesic effect during exercise,
occlusion, and recovery, Figure 2.3. This result is not substantiated by the main body of
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research emphasizing the analgesic effects of transcutaneous neurostimulation. It is
possible that paresthesia associated with the vibrational mechanoreception of
neurostimulation near the ganglia was interpreted by first-time neurostimulation users as
“pain,” creating arbitrarily high pain measurements with TENS and IFC treatments. In
subsequent studies, participants will be instructed to concentrate on pain originating
exclusively in their treatment arm to promote specificity.
The increase in local blood flow during exercise and immediately following the
release of an upstream occlusion, Figure 2.4, may be explained by metabolic
vasodilation and reactive hyperemia, respectively. Metabolic byproducts released during
exercise cause vascular smooth muscle cells to relax, resulting in vasodilation and
increased blood flow. These byproducts also activate the metaboreflex, which in turn
selectively inhibits sympathetic vasoconstriction in active tissues in a process known as
functional sympatholysis. Reactive hyperemia, or the rapid increase in perfusion
following ischemia, is attributed to the release of local vasodilator metabolites in hypoxic
tissues.
We hypothesized that neurostimulation activates peripheral α-2 adrenergic
receptors, inhibiting norepinephrine release and decreasing local sympathetic tone [73].
This results in an increase in blood flow independent of functional sympatholysis or
reactive hyperemia. However, at this sample size (n=6), we did not see sufficient
evidence that neurostimulation has a hyperemic or an analgesic effect. Moving forward, a
larger sample size would allow us to improve our predictive power. We must also control
for vasodilation mediated by local metabolites following ischemia. To isolate TENS or
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IFC-induced hyperemia from metabolically-induced hyperemia, pilot study II will
incorporate a control treatment without post-exercise occlusion (PECO-).
Since there were no significant differences in pain or blood flow between 100 Hz
and 20 Hz frequencies for either TENS or IFC treatment, future work will use a standard
100 Hz frequency to control for possible effects of frequency on Aβ fiber activation
similar to frequency settings used in comparator studies [51, 32].
2.3 PILOT STUDY II
2.3.1 Methods
Pilot study II was conducted on 9 healthy Cal Poly students age 18-23.
Treatments were blinded, randomized, and followed by 10-minute rest periods. TENS
and IFC settings were standardized for every treatment at 100 Hz frequencies, though the
main protocol for pilot study II closely followed pilot study I.
Study II controlled for the metaboreflex by selectively applying the occlusion and
comparing trends in blood flow with (PECO+) and without (PECO-) ischemia. A blocked
experimental design was used to evaluate both TENS and IFC treatments in relation to a
placebo (sham) treatment. Each participant received a total of six treatment combinations:
TENS, PECO+; TENS, PECO-; IFC, PECO+; IFC, PECO-; placebo, PECO+; and
placebo, PECO-. Completing all six treatment types on the same individual allowed us to
control for differences in neural and cardiovascular physiology between subjects.
Furthermore, pilot study II individualized the intensity of the neurostimulation for
every treatment session to account for differences in pain tolerances between participants.
At the beginning of each treatment, the stimulus amperage was increased from 0 mA to
the subject’s personal pain tolerance threshold, then dropped 1 mA and held constant
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throughout the rest of the session. If the motor threshold was reached before the pain
threshold such that involuntary muscle twitching occurred, as seen in 2 of the 9 subjects,
the intensity was dropped to 1 mA below motor threshold.
Hemodynamic and pain responses were measured and analyzed similarly to pilot
study I. Absolute change and percent change models were run for both responses and
percent change had more statistical power (higher R2) for change in blood flow with the
pilot study II dataset. Therefore, pain data was analyzed in terms of absolute change
while blood flow data was analyzed in terms of percent change. Two-way ANOVA for
repeated measures and Tukey-Kramer post hoc analysis were completed in Minitab.
2.3.2 Results
2.3.2.1 Pain
Similar to the trends in pilot study I, NRS pain trended to increase during exercise
and when occlusion was applied (Placebo+, TENS+, IFC+). Indeed, pain increased each
successive minute during occlusion (t=6-9 min), Figure 2.5. In contrast to pilot study I,
both TENS and IFC treatments trended to lower ischemic pain during occlusion in pilot
study II, Figure 2.6.
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Figure 2.5: Absolute Pain across Time during Pilot Study II. Absolute pain every
minute during baseline, exercise, occlusion, and recovery phases for each treatment
combination (n=9). Values are shown as mean ± SE. *p≤0.05 for ∆pain vs. time.

Figure 2.6: Change in Pain during Pilot Study II. Change in mean pain (n=9) from
baseline over A. Time (Baseline, Exercise, Occlusion, and Recovery phases), B.
Neurostimulation type (IFC, Placebo, TENS), and C. Ischemia (PECO-, PECO+).
*p≤0.05 for ∆pain vs. time, neurostimulation treatment, & ischemia.
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2.3.2.2 Blood Flow
As expected, blood flow increased during exercise, decreased during occlusion
(+), and increased during recovery following occlusion, Figure 2.7A. When occlusion is
not applied, blood flow increases during exercise and remains above baseline for the
following 9 minutes, Figure 2.7C. Interestingly, blood flow increased in the contralateral
arm with IFC treatment during occlusion and remained elevated during recovery, Figure
2.7B, while without occlusion there was no difference in blood flow with IFC treatment,
Figure 2.7D. Another interesting trend was seen in contralateral blood flow with TENS
treatment, as TENS increased blood flow during exercise while IFC and placebo
treatments did not (confidence interval included 0 %∆), Figure 2.7B,D.
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Figure 2.7: %Change in Blood Flow during Pilot Study II. Percent change in blood
flow from baseline during exercise, occlusion, and recovery phases with TENS (n=9) and
IFC (n=9) with occlusion (PECO+) in the A. treatment (dominant) and B. contralateral
hands, and without occlusion (PECO-) in the C. treatment and D. contralateral hands.
Values are shown as mean ± SE. *p≤0.05 for %∆blood flow vs. phase.

2.3.3 Discussion
To test the hypothesis that TENS and IFC stimulation have different effects on
perfusion and analgesia, pilot study II compared changes in blood flow and pain elicited
by both modalities before, during, and after acute ischemia. In contrast to hyperanalgesic
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trends seen in pilot study I, pilot study II showed analgesic trends associated with both
TENS and IFC during occlusion as predicted, Figures 2.5, 2.6. We also saw that
ischemic pain increased in severity in a similar manner for placebo, TENS, and IFC
treatments the longer the occlusion was maintained, though the maximal change in pain
was relatively low on the NRS pain scale.
It is possible that the analgesic effects of neurostimulation are more pronounced
with chronic pain in diseased patients than with acute experimental pain in healthy
patients [38]. Instead, future studies will evaluate pain in a quantitative manner using the
Numeric Rating Scale (NRS) as well as in a qualitative manner using the Faces and Short
Form McGill Pain Questionnaire (SF-MPQ) scales, Appendices H, I. This may help to
better measure changes in uncomfortable sensations at lower pain stimulus intensities.
The increase in blood flow observed during recovery when occlusion was applied
(+ treatments) and static blood flow observed when occlusion was not applied (treatments), Figure 2.7, supports the hypothesis that reactive hyperemia is independent of
electrical stimulation. Additionally, the observed differences in blood flow with TENS
during exercise and with IFC during occlusion indicate that pulsed biphasic and burstmodulated alternating stimulus waveforms may have different effects on blood flow.
However, there was no evidence that TENS or IFC had an overall analgesic or
hyperemic effect independent of metabolic demands. Healthy young subjects (n=11)
similar to our study population have shown increased calf blood flow with local TENS
treatment at rest, during exercise, and during occlusion as compared to placebo treatment
[32], Figure 2.8, supporting the hypothesis that neurostimulation can increase blood flow
through a secondary mechanism such as Aβ fiber activation.
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It is possible that electrodes were not consistently placed over the C7 and T4
ganglion during each trial, resulting in an arbitrarily high type II error in our pain and
blood flow results. To improve consistency, electrode pads will not be removed from the
participant’s back during the resting period between trials. The accuracy of electrode
placement will also be improved by receiving instruction from a licensed physical
therapist on how to palpate for the C7 and T4 vertebrae prior to attaching the electrode

%∆

pads to the skin.

Figure 2.8: %Change in Calf Blood Flow in Comparator Study. TENS treatment
increased blood flow regardless of exercise or ischemia in healthy young subjects similar
to our study population [32]. Values are shown as mean ± SE. *p≤0.05 for %∆CBF vs.
time.
2.4 PILOT STUDY III
2.4.1 Methods
Pilot study III focused on expanding our pain measurement techniques. A
protocol very similar to pilot study II was performed on 9 healthy Cal Poly students age
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18-23. Treatments were blocked by neurostimulation (TENS/placebo) and occlusion
(PECO+/PECO-) and performed in a randomized, single-blinded manner. Pain was
assessed at 60 second intervals using both quantitative and qualitative pain scales: the
Numeric Rating Scale (NRS) and Faces scale, respectively, Appendix H. Participants
verbalized their numeric pain on a scale of 0 – 10, and then identified which face (A – G)
best described their pain. Lettered scores were assigned weights of 0 – 6, respectively, for
quantitative analysis. A SF-MPQ was administered orally halfway through both the
exercise phase and the occlusion phase with the participant rating each descriptor as
‘none, mild, moderate, or severe,’ Appendix I. These qualitative scores were assigned
weights of 0, 1, 2, and 3, respectively, for quantitative analysis, Figure 2.9.

Figure 2.9: Sample Pain Measurement Consolidation and Normalization. NRS and
Face pain measurements were consolidated down into one summary value for each phase.
The NRS values were summed for both the E and O phases and the sum recorded as the
absolute pain measurement for that phase. The Face letters were assigned numerical
weights (A=0, B=1, C=2, ect.) and the highest weight recorded for each phase. The
absolute values were then normalized to the baseline values by taking the difference
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between that phase and baseline. The normalized values were used for quantitative
analysis.
2.4.2 Results
All three scales show the same trends in pain for each neurostimulation type,
Figures 2.10, 2.11, 2.12. As expected, pain increased with occlusion. However, pain
trends observed during TENS treatments were no different than trends observed during

Mean ∆ NRS Pain

placebo treatments.

A

B

D

C

Figure 2.10: Mean Change in Pain during Pilot Study III Using the NRS Pain Scale.
Change in average pain compared across A. Subject (n=9), B. Neurostimulation (TENS,
Placebo), C. Ischemia (+/-), and D. In relation to neurostimulation with and without
ischemia (P-, P+, T-, T+).
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Figure 2.11: Mean Change in Pain during Pilot Study III Using the Faces Pain
Scale. Change in average pain compared across A. Subject (n=9), B. Neurostimulation
(TENS, Placebo), C. Ischemia (+/-), and D. In relation to neurostimulation with and
without ischemia
(P-, P+, T-, T+).
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Figure 2.12: Mean Change in Pain during Pilot Study III Using the MPQ Pain
Scale. Change in average pain compared across A. Subject (n=9), B. Neurostimulation
(TENS, Placebo), C. Ischemia (+/-), and D. In relation to neurostimulation with and
without ischemia
(P-, P+, T-, T+).

2.4.3 Discussion
Although the NRS, Faces, and MPQ pain scales used different schemes (numeric,
associative, and descriptive, respectively) to quantify the intensity of ischemic pain, all
three scales resulted in increased pain trends for TENS treatments. Interestingly, the exact
same protocol that resulted in analgesic trends with TENS in pilot study II resulted in
hyperalgesia in pilot study III. This inconsistency in results warrants a fourth pilot study
to determine our ability to replicate our results before beginning a larger trial with an
appropriately powered sample size.
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2.5 PILOT STUDY IV
2.5.1 Methods
Pilot study IV was conducted in the same manner as pilot study III on 12 healthy
Cal Poly students age 18-23. Treatments were blocked by neurostimulation
(TENS/IFC/placebo) and occlusion (PECO+/PECO-) and performed in a randomized,
single-blinded manner. Pain was assessed at 60 second intervals using the NRS and Faces
scales and an SF-MPQ was administered during each phase. The SF-MPQ was modified
to include 5 paresthesia descriptors in addition to the 25 pain descriptors to allow
participants to identify both paresthesia and pain sensations associated with ischemia.
2.5.2 Results
2.5.2.1 Pain
As expected, occlusion (ischemia +) was correlated with an increase in pain both
during ischemia and immediately following occlusion, Figure 2.13. Interestingly,
neurostimulation itself was painful without occlusion (ischemia -) in the first few minutes
after exercise, Figure 2.13A, but not at later time points (ischemia -), Figure 2.13B.

37

Mean ∆ MPQ Pain

B

A

Figure 2.13: Mean Change in Pain during Pilot Study IV Using the MPQ Pain Scale.
A. Pain increased during occlusion (ischemia +) for IFC, TENS, and Placebo treatments,
though TENS and IFC caused an increased pain without occlusion (ischemia -). B. Pain
increased during recovery following occlusion (ischemia +) for IFC, TENS, and Placebo
treatments.

2.5.2.2 Blood Flow
Hyperemic trends occurred with the release of an occlusion during the recovery
phase, as expected. In pilot study II, both TENS and IFC amplified hyperemic trends
compared to placebo treatments, possibly supporting the hypothesis that neurostimulation
has a hyperemic effect in ischemic tissues, Figure 2.14A. However, TENS and IFC
trended similarly to placebo treatments in pilot study IV, Figure 2.14B.
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Mean ∆ Blood Flow [PU]
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Figure 2.14: Comparison of Mean ΔBlood Flow during Recovery for Pilot Study II
and IV. Blood flow increased following occlusion (ischemia +) for IFC, TENS, and
Placebo treatments. ΔBlood flow A. During pilot study II showed a greater hyperemic
trend with IFC and TENS treatments, while B. During pilot study IV all three treatments
trended similarly.

2.5.3 Discussion
Including paresthesia in our pain measurements allowed us to better quantify
paresthesias being interpreted as painful stimuli by subjects using TENS and IFC.
Paresthesia significantly increased “pain” in resting, non-occluded tissues with
neurostimulation treatments as compared to placebo treatments in the 4th-6th minutes of
the protocol (“occlusion phase”) but not in the 7th-9th minutes (“recovery phase”). It is
possible that peripheral nociceptors adapted to paresthesia such that participants felt the
sensation at earlier time points but not later time points.
It is also possible that the static handgrip exercise itself was painful, resulting in
increased pain sensations in the 3 minutes immediately following exercise that subsided
over time [74]. To reduce pain associated with the handgrip exercise, we will procure to a
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more ergonomic hand dynamometer (iWorx, San Luis Obispo, CA, USA) for the clinical
study.
Although there were no statistically significant differences in blood flow observed
with neurostimulation, the exaggerated hyperemic trends associated with TENS and IFC
seen in pilot study II were not duplicated in pilot study IV. While these trends are not
consistent between the two pilot studies, we must increase our statistical power before
confident conclusions can be made. To this effect, our clinical study will use a much
larger sample size than the pilot studies with the goal of finding a definitive effect of
neurostimulation on perfusion. Sample size will be determined by a power analysis using
the pain and blood flow data variability observed between subjects in pilot study IV.
Furthermore, instead of looking at only blood flow measurements, we will account for
SNS control of systemic perfusion by incorporating blood pressure measurements.
Moving forward, whole-limb perfusion will be evaluated in terms of vascular
resistance (∆𝑅𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 = ∆𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒/∆𝐹𝑙𝑜𝑤). We will also control for caffeine, a
known vasoconstrictor, to more accurately evaluate sympathetically-mediated changes in
vascular tone.
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CHAPTER 3: CLINICAL STUDY

3.1 INTRODUCTION
3.1.1 Proposed Hemodynamic Mechanism of TENS and IFC
The main body of research involving TENS and IFC focuses on their analgesic
effects on neuromuscular pain, which can be explained by the gate control theory.
However, it is also postulated that neurostimulation increases blood flow to the
peripheries via a related pathway. In the context of PAOD, increased blood flow to
ischemic peripheral tissues should also reduce pain, resulting in an additive analgesic
effect. This focus of this study is to investigate hemodynamic responses to
neurostimulation during acute ischemia. Although the mechanism is unclear, electrical
stimulation may suppress local sympathetic tone and ischemic pain by activating Aβ
fibers (large-diameter) parallel to the nociceptive C fibers (small-diameter) in the dorsal
horn. Ganglial stimulation of Aβ fibers initiates an efferent action potential that
propagates down to α-2 adrenergic receptors (α-2A-Rs) in vascular sympathetic nerve
terminals. α-2A-Rs are coupled to voltage-dependent N-type calcium channels via a G
protein. α-2A-R activation inhibits calcium influx responsible for presynaptic
norepinephrine release, resulting in localized vasodilation and ultimately increased blood
flow and reduced ischemic pain in the affected tissues [73].
3.1.2 Study Aims and Hypotheses
To our knowledge, there have been no previous studies directly comparing the
hemodynamic effect of TENS and IFC, although studies with similar protocols have
investigated each individually [32, 52]. The main goal of the preclinical work was to
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develop protocols for investigating changes in vascular resistance and perceived pain
elicited by both neurostimulation techniques and to a placebo (control) treatment.
We hypothesized that transcutaneous neurostimulation will increase blood flow
and decrease vascular resistance, possibly due to a decrease in sympathetic activity. This
may occur both indirectly from a decrease in metaboreflex activation and directly from
selective inhibition of norepinephrine release.
Additionally, we hypothesize that TENS and IFC neurostimulation modalities will
have differing effects on blood flow and vascular resistance. It is possible that the
sinusoidal waveform in IFC may more readily overcome skin impedance than the
biphasic pulsed waveform characteristic of TENS and thus have a more significant effect
on the Aβ afferent fibers, resulting in a greater inhibitory effect on pain and sympathetic
tone. We further hypothesized that IFC may have a greater hyperemic effect than TENS
as its current waveform may be more efficient at overcoming skin impedance. Lastly, we
hypothesize that vascular resistance will inversely correlate to ischemic pain, Table 3.1.

Table 3.1: Expected Trends for Hemodynamic Factors and Pain during Recovery.

Expected Outcome

Placebo

TENS

IFC

PECO- PECO+ PECO- PECO+ PECO- PECO+

Heart Rate

-

-

↓

↓↓

↓

↓↓

Skin Temperature

-

↑

↑

↑↑

↑

↑↑

Mean Blood Pressure

-

↓

↓

↓↓

↓

↓↓

Local Blood Flow

-

↑

↑

↑↑

↑

↑↑

Contralateral Blood Flow

-

↑

-

↑↑

-

↑↑

Vascular Resistance

-

↓

↓

↓↓

↓

↓↓

Ischemic Pain

-

↓

↓

↓↓

↓

↓↓
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3.2 STUDY PARTICIPANTS
The preclinical study was performed on 45 healthy Cal Poly students aged 18 to
23 years. All participants completed an Informed Consent form (Appendix A), a Medical
History Questionnaire (Appendix B), and a W9 Tax Form (Appendix C), prior to
treatment, the latter for acquiring participant compensation in the form of a $25 Visa gift
card. These forms, along with all hemodynamic and pain data, were kept confidential
with the exception of the W9 form which was submitted to the Sponsored Programs
department.
The Medical History Questionnaire was reviewed by the primary researcher prior
to starting treatment. Any contraindications for transcutaneous neurostimulation, i.e.
pregnancy or history of epilepsy, cardiovascular disease, dermatitis, syncope, or chronic
pain, were grounds for dismissal. Furthermore, participants fasted from caffeine for at
least 12 hours prior to the treatment, as caffeine is a known vasoconstrictor. This
information, as well as age and body mass data, was also collected on the Questionnaire.
No participants were dismissed as a result of medical contradictions or non-compliance
with fasting from caffeine.
All recruitment and experiments were performed in accordance with a protocol
approved by the Cal Poly Human Subjects Committee. The petition for approval
(Appendix D), Overview PowerPoint (Appendix E), and a detailed protocol (Appendix
F) can be found in the appendices.
3.3 MATERIALS AND METHODS
Similar to the pilot studies, the hypothesis that neurostimulation increases
perfusion during acute ischemia was evaluated by measuring mean blood pressure (MBP)
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and blood flow (BF) before, during, and after ischemia. These response variables were
then combined into terms of vascular resistance (VR) to assess the conductive effect of
neurostimulation (∆𝑅𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 = ∆𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒/∆𝐹𝑙𝑜𝑤). To test the hypothesis that
neurostimulation diminishes sympathetic tone, we also measured heart rate (HR) as
decreased HR would be indicative of decreased SNS activity. Since the stimulus is
applied at the ganglion, we expected to see a similar decrease in SNS activity along the
same dermatome in the contralateral limb.
Lead electrodes and their corresponding ground electrodes were aligned with the
vertebrae approximately two inches from either side of the spinal column in a quadripolar
formation, Figure 2.1. To ensure accurate electrode placement, participants wore a loose
shirt or tank top to allow access to the upper back and the C7 and T4 vertebrae were
identified via manual palpation. Participants sat in a relaxed position with their arms
supinated and four neurostimulation leads (InTENSity TENS/IFC Combination
Stimulator, Current Solutions LLC) were attached to the participant’s upper back with reusable carbon electrode pads (Tyco Gel Pads, Santamedical). Both the TENS and IFC
treatments involved 50 µs pulses at a rate of 100 pps at intensities below the motor
threshold (1-15 mA). An optic Laser Doppler Flowmetry (LDF) skin probe (VP1 probe,
Moor Instruments) was adhered to each palm using double sided adhesive (PADs, Moor
Instruments). The probe cables coupled to a LDF data acquisition unit (moorVMS-LDF,
Moor Instruments), which output to a PowerLab DAQ and digital chart recording
software (LabChart 8.0).
A skin thermistor (ADI Instruments) was taped to the palm before an ergonomic
hand grip dynamometer (iWorx) was gripped in the dominant hand. Post-exercise
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circulatory occlusion (PECO) mimicked acute ischemia, which is present in patients with
PAOD, in otherwise healthy subjects by inflating a manual blood pressure cuff to 180
mmHg on the forearm of the treatment arm for 3 minutes. An automated blood pressure
cuff was applied to the contralateral upper arm to measure MBP and HR every 2.5
minutes as specified in the monitor’s instructions for use (Omron 7 Series Wireless
Upper Arm Blood Pressure Monitor, BP761), Figure 2.2. Data recordings were compiled
into a master spreadsheet for later analysis, Appendix G.
A crucial part of the experimental design was distinguishing between changes in
vascular tone related to neurostimulation versus vasoactive reflexes such as the
metaboreflex. To selectively induce acute ischemia and examine the effects of both
TENS and IFC in relation to a placebo treatment, each treatment type was applied with
(PECO+) and without (PECO-) vascular occlusion. A randomized blocked experimental
design ensured that each participant received a total of six treatment combinations:
TENS, PECO+; TENS, PECO-; IFC, PECO+; IFC, PECO-; placebo, PECO+; and
placebo, PECO-. Neurostimulation leads were always applied to the participant’s back
regardless of treatment type to help maintain a single-blinded study. The participant was
never notified of which treatment type was being applied, and all sensors and cuffs were
applied the same way for every treatment. Treatment order was randomized and
treatments were performed consecutively. A 10-minute rest period was allotted between
trials to minimize fatigue. The intensity of the neurostimulation was individualized for
every session and held constant below the motor and pain thresholds.
After familiarizing the participant with the monitoring equipment, pain scales, and
protocol, a resting baseline was recorded for one minute, followed by three minutes of
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handgrip exercise, Figure 3.3. Maximal handgrip force of the dominant hand was
determined by the highest output obtained in three trials, each 1 second in duration. A
static grip exercise at 30% of maximal grip force was then maintained for the remainder
of the 3 minutes. Next, for PECO+ treatment types, the participant released the hand
dynamometer and the blood pressure cuff on the treatment forearm was manually inflated
to 180 mmHg for 3 minutes to induce ischemia in the treatment hand. For PECOtreatment types, the blood pressure cuff was not inflated and the participant released the
dynamometer. At the 7th minute, the blood pressure cuff was released and a one minute
recovery period was recorded.

Figure 3.1: Protocol Flowchart. After the neurostimulation treatment type (placebo,
TENS, or IFC) was turned on and the intensity adjusted to below the pain and motor
thresholds, the 1 minute of baseline was recorded, followed by 3 minutes of static
handgrip exercise, 3 minutes of PECO+/PECO-, and 1 minute of recovery.
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Pain was assessed at 60 second intervals using the Numeric Rating Scale (NRS)
and Faces scale, Appendix H. A modified Short-Form McGill Pain Questionnaire (mSFMPQ), Appendix I, was administered halfway through both the exercise phase and the
occlusion phase to allow participants to identify both paresthesia and pain sensations
associated with ischemia.
Raw data was separated into four phases according to the experimental protocol:
baseline, exercise, occlusion, and recovery, Figure 3.2. Hemodynamic responses were
averaged for 30 second intervals during each phase and then expressed as an absolute
change from the baseline value. All experimentally measured hemodynamic factors,
including skin temperature (°C), respiratory rate (BPM), and local and contralateral blood
flow (PU), were compared by two-way ANOVA for repeated measures while interactions
between each factor and treatment phase and ischemia were compared by three-way
ANOVA for repeated measures using JMP statistical software. Post hoc comparisons
were analyzed using Tukey-Kramer’s method, Appendix M.
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Occlusion
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D
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A

Figure 3.2: Raw Data Traces by Phase. The raw data traces were sectioned by phase
and averaged for 30 second intervals for all experimentally measured hemodynamic
factors including A. Skin temperature (°C), B. Respiratory rate (BPM), C. Grip force (N),
D. Local blood flow (PU), E. Contralateral blood flow (PU).
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3.4 DATA ANALYSIS
3.4.1 Change in Vascular Resistance
To examine the relationship between neurostimulation and perfusion under
ischemic and non-ischemic tissue conditions, we first determined the importance of
dependent study variables, including subject, treatment type, ischemia, and phase, on
̅̅̅̅ ) using two and three-way ANOVAs
each other and on the average change in VR (∆𝑉𝑅
̅̅̅̅ incorporates both flow and pressure
for repeated measures. Since the calculation for ∆𝑉𝑅
̅̅̅̅ is the best approximation of cutaneous perfusion and therefore is the
measurements, ∆𝑉𝑅
̅̅̅̅ was calculated as:
response variable in our statistical analysis. ∆𝑉𝑅
̅̅̅̅ =
∆𝑉𝑅

̅̅̅̅̅̅̅ 𝑚𝑚𝐻𝑔
∆𝑀𝐵𝑃
,[
]
̅̅̅̅̅̅
𝑃𝑈
∆𝐶𝐵𝐹

where
̅̅̅̅̅̅̅ = ∆𝐷𝐵𝑃
̅̅̅̅̅̅ +
∆𝑀𝐵𝑃

̅̅̅̅̅̅ − ∆𝐷𝐵𝑃
̅̅̅̅̅̅
∆𝑆𝐵𝑃
, [𝑚𝑚𝐻𝑔]
3

and 𝑃𝑈 is an arbitrary Perfusion Unit of Doppler velocimetry that approximates
cutaneous blood flow.
̅̅̅̅ dataset was left-skewed and required transformation to fit the criteria for
The ∆𝑉𝑅
normality in ANOVA testing. The data were rectified by adding 10 mmHg/PU to each
̅̅̅̅value and subsequently transformed using a base 10 logarithm. This transformed the
∆𝑉𝑅
data into a normal distribution for further statistical analysis. Thus, the experimental
changes in perfusion were modeled using phase, treatment type, and ischemia as
̅̅̅̅ as the dependent response
independent variables, subject as a random variable, and ∆𝑉𝑅
variable. The shorthand prediction expression is:
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̅̅̅̅̅̅ + Phase + Treatment + Phase*Treatment + Ischemia +
log10(VR+10) = ∆𝑉𝑅
Phase*Ishcemia + Treatment*Ischemia + Phase*Treatment*Ischemia + Subject
This expression is written as a general linear model in the form:
𝑦𝑖𝑗 = 𝜇𝑖𝑗 + 𝛼1 + 𝛼2 + 𝛼1 𝛼2 + 𝛼3 + 𝛼1 𝛼3 + 𝛼2 𝛼3 + 𝛼1 𝛼2 𝛼3 + 𝜀𝑖𝑗
where
̅̅̅̅)
𝜇𝑖𝑗 = Average Change in Vascular Resistance (∆𝑉𝑅
𝛼𝐸
̅̅̅̅
𝛼1 = {𝛼𝑂 } = Effect of phase (E, O, or R) on ∆𝑉𝑅
𝛼𝑅
𝛼𝑇
̅̅̅̅
𝛼2 = { 𝛼𝐼 } = Effect of treatment type (TENS, IFC, or placebo) on ∆𝑉𝑅
𝛼𝑃
𝛼𝑃𝐸𝐶𝑂+
̅̅̅̅
𝛼3 = {𝛼
} Effect of ischemia (PECO+ or PECO-) on ∆𝑉𝑅
𝑃𝐸𝐶𝑂−
𝜀𝑖𝑗 = Residuals, or errors around the predicted trendline
This model allowed us to test the hypothesis that neurostimulation decreases
vascular resistance. However, because the effects of treatment phase and ischemic
conditions can impact the effects of TENS and IFC on perfusion, we evaluated the
interactions between treatment type, treatment phase, and ischemia. We also accounted
for between-subject variability by including subject in the model.
Due to the complexity of the model, statistical signiﬁcance was accepted when p
≤ 0.01. This allowed for only a 7% probability of falsely obtaining the observed effect in
the sample data, assuming our model with 7 fixed input factors was reasonable. No data
points were excluded as outliers, and it was reasonable to assume equal variance in the
dataset (Levene: p > 0.05). The expanded prediction expression may be seen in
Appendix J.
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3.4.2 Change in Pain
Pain data was analyzed for each pain scale in relation to subject, treatment type,
ischemia, and phase using two and three-way ANOVAs for repeated measures. The
experimental changes in pain were modeled as a function of phase, treatment type,
ischemia, and subject. Statistical signiﬁcance was accepted when p ≤ 0.05. The shorthand
prediction expression is:
∆Pain = ̅̅̅̅̅̅̅̅
∆𝑃𝑎𝑖𝑛 + Phase + Treatment + Phase*Treatment + Ischemia +
Phase*Ishcemia + Treatment*Ischemia + Phase*Treatment*Ischemia + Subject
This expression is written as a general linear model in the form:
𝑦𝑖𝑗 = 𝜇𝑖𝑗 + 𝛼1 + 𝛼2 + 𝛼1 𝛼2 + 𝛼3 + 𝛼1 𝛼3 + 𝛼2 𝛼3 + 𝛼1 𝛼2 𝛼3 + 𝜀𝑖𝑗
where
𝜇𝑖𝑗 = Average Change in Pain (∆𝑃𝑎𝑖𝑛)
𝛼𝐸
𝛼1 = {𝛼𝑂 } = Effect of phase (E, O, or R) on ∆𝑃𝑎𝑖𝑛
𝛼𝑅
𝛼𝑇
𝛼2 = { 𝛼𝐼 } = Effect of treatment type (TENS, IFC, or placebo) on ∆𝑃𝑎𝑖𝑛
𝛼𝑃
𝛼𝑃𝐸𝐶𝑂+
𝛼3 = {𝛼
} Effect of ischemia (PECO+ or PECO-) on ∆𝑃𝑎𝑖𝑛
𝑃𝐸𝐶𝑂−
𝜀𝑖𝑗 = Residuals, or errors around the predicted trendline
The expanded prediction expression is in Appendix K.
This model allowed us to test the hypothesis that neurostimulation decreases pain
perception. However, because the effects of treatment phase and ischemic conditions can
impact the analgesic effects of TENS and IFC, we evaluated the interactions between
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treatment type, treatment phase, and ischemia. We also accounted for between-subject
variability by including subject in the model.
3.4.3 Change in Vascular Resistance associated with Change in Pain
The next step was to create a model to examine a possible relationship between
changes in pain and changes in cutaneous perfusion associated with neurostimulation
under ischemic and non-ischemic tissue conditions. Similar to the first model, inputs
̅̅̅̅ as the response variable.
included subject, treatment type, ischemia, and phase, with ∆𝑉𝑅
However, this model also included pain measurements as a fixed input. The MPQ pain
scale was the most successful at detecting changes in pain during exercise and occlusion
and was therefore used in this model. However, ∆pain during the recovery period is
̅̅̅̅ during
assumed to be zero in this model. If the correlation between ∆pain and ∆𝑉𝑅
recovery is of interest, the NRS or Faces pain scale should be used as the response
̅̅̅̅ and
variable. The shorthand prediction expression for the relationship between ∆𝑉𝑅
∆MPQ pain is:
log10(VR+10) = ̅̅̅̅̅̅
∆𝑉𝑅 + Phase + Ischemia + Treatment + ∆MPQ + Phase*∆MPQ +
Ischemia*∆MPQ + Treatment*∆MPQ + Subject
This expression is written as a general linear model in the form:
𝑦𝑜 = 𝛽𝑜 + 𝛼1 + 𝛼2 + 𝛼3 + 𝛽1 𝑥𝑖 + 𝛽1 𝛼1 + 𝛽1 𝛼2 + 𝛽1 𝛼3 + 𝜀𝑜
where
̅̅̅̅)
𝛽𝑜 = Average Vascular Resistance (∆𝑉𝑅
𝛼𝐸
̅̅̅̅
𝛼
𝛼1 = { 𝑂 } = Effect of phase on ∆𝑉𝑅
𝛼𝑅
𝛼𝑇
̅̅̅̅
𝛼2 = { 𝛼𝐼 } = Effect of treatment type on ∆𝑉𝑅
𝛼𝑃
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𝛼𝑃𝐸𝐶𝑂+
̅̅̅̅
𝛼3 = {𝛼
} Effect of ischemia on ∆𝑉𝑅
𝑃𝐸𝐶𝑂−
̅̅̅̅; slope change
𝛽1 = Effect of ∆MPQ pain on ∆𝑉𝑅
𝜀𝑜 = Residuals, or errors around the predicted trendline
The complexity of the model warranted statistical signiﬁcance at p ≤ 0.01. No data points
were excluded as outliers, and it was reasonable to assume equal variance in the dataset
(Levene: p > 0.05). The expanded prediction expression is in Appendix L.
This model allowed us to test the possible correlation between change in vascular
resistance and change in pain. However, because the effects of treatment phase and
ischemic conditions have compounding effects on perfusion and pain independent of
neurostimulation, we evaluated the interactions between TENS/IFC, treatment phase, and
ischemia. We also accounted for between-subject variability by including subject in the
model.
3.5 RESULTS
To test the hypothesis that neurostimulation increases perfusion and decreases
SNS tone (based on reduction in HR), the absolute changes in local BF, contralateral BF,
HR, MBP, VR, and ischemic pain were divided into phase, treatment type, and ischemic
condition for analysis, Appendix M and N. Change in vascular resistance and change in
pain were modeled separately and together in JMP statistical software based on the
effects of phase (Exercise, Occlusion, Recovery), treatment type (TENS, IFC, Placebo),
and ischemia (PECO+, PECO-), Appendix O.
3.5.1 Change in Blood Flow
As expected, blood flow in the treatment arm (termed local blood flow) increased
from resting baseline during exercise due to increased metabolic demand, decreased
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during occlusion due to manual compression of the arterioles, and increased rapidly
during the recovery phase due to reactive hyperemia. However, neither neurostimulation
treatment increased blood flow as compared to placebo treatment, though interestingly
both TENS and IFC have a general trend towards decreased blood flow in both ischemic
and non-ischemic conditions, Figure 3.3. During occlusion, TENS and IFC tend to
exaggerate ischemia, while during recovery, TENS and IFC tend to dampen reactive
hyperemia. Interestingly, both forms of neurostimulation appear to have a latent
inhibitory effect on blood flow under non-ischemic conditions after exercise.
A
B

*

*

C

Figure 3.3: Effects of Phase, Treatment, and Ischemia on ΔBlood Flow. A. Local
blood flow (PU) data trace showing increased blood flow during exercise, reduced flow
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during occlusion, and reactive hyperemia during recovery. B. Contralateral blood flow
data trace (PU). Arrows indicate the major drops in perfusion associated with blood
pressure measurements. C. Change in local blood flow (PU) by phase, treatment type,
and ischemia. Values are shown as mean ± SE. *p≤0.05 for ∆blood flow vs. ischemia &
phase.

3.5.2 Change in Vascular Resistance
̅̅̅̅ is reflective of changes in both blood flow and pressure and therefore gives a
∆𝑉𝑅
more complete picture of the effects of neurostimulation on perfusion in ischemic tissues.
̅̅̅̅, and ∆𝑉𝑅
̅̅̅̅ decreases during reactive hyperemia
As expected, occlusion increases ∆𝑉𝑅
following occlusion, Figure 3.4. The increase in ̅̅̅̅
𝑉𝑅 during the exercise phase cannot be
attributed to the occlusion, indicating that static exercise itself creates ischemic
conditions.
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̅̅̅̅), [log10(mmHg/PU)]
log10(∆𝑉𝑅
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Figure 3.4: Effects of Phase, Treatment, and Ischemia on ∆Vascular Resistance.
̅̅̅̅ both directly and indirectly through interactions.
These factors affect the normalized ∆𝑉𝑅
̅̅̅̅ . B. Effect of treatment type on ∆𝑉𝑅
̅̅̅̅ . C. Effect of ischemia on
A. Effect of phase on ∆𝑉𝑅
̅̅̅̅. D. Effect of interaction between phase and ischemia on ∆𝑉𝑅
̅̅̅̅. E. Effect of
∆𝑉𝑅
̅̅̅̅. F. Effect of interaction between
interaction between phase and treatment on ∆𝑉𝑅
̅̅̅̅. Values are shown as log10(means) ± SE. *p≤0.05 for
treatment and ischemia on ∆𝑉𝑅
̅̅̅̅ vs. phase, treatment, & ischemia.
∆𝑉𝑅

̅̅̅̅ as compared to placebo under acute ischemic
Interestingly, IFC increases ∆𝑉𝑅
̅̅̅̅ during occlusion, Figure 3.5.
conditions while there is no effect of TENS on ∆𝑉𝑅
Furthermore, the latent effect observed in the blood flow data is reflected in the vascular
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̅̅̅̅ 7-9 minutes after static exercise under
resistance data. Both TENS and IFC increase ∆𝑉𝑅
non-ischemic conditions, though during reactive hyperemia this effect is lifted as the
tissues recover from the acute ischemic event.

---------------*--------------*

*
---------*-----------------*---------

Figure 3.5: Mean Changes in Vascular Resistance for TENS, IFC, and Placebo
̅̅̅̅ as
Treatments during each Phase and Ischemic Condition. IFC increases ∆𝑉𝑅
̅̅̅̅ under noncompared to placebo during ischemia, and both TENS and IFC increase ∆𝑉𝑅
ischemic conditions versus ischemic conditions during the recovery phase following
̅̅̅̅ vs. phase, treatment,
acute ischemia. Values are shown as means ± SE. *p≤0.05 for ∆𝑉𝑅
& ischemia.

3.5.3 Change in Pain
As previously mentioned, three separate scales were used to assess pain and
paresthesia to discern the effect of neurostimulation on ischemic pain. Pain was assessed
during the exercise and occlusion phases using the MPQ scale and every minute using the
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NRS and Faces scales. To compare trends from each phase of the treatment, the pain data
from the NRS and Faces scales were consolidated into the four main phases of the
protocol and normalized to baseline. All three scales captured ischemic pain associated
with occlusion, though one of the scales show a difference between TENS, IFC, or
placebo treatment types in their effect on ischemic pain, Figure 3.6, Appendix O Table
III.B. The MPQ scale shows the greatest difference in ∆pain during the occlusion phase
under ischemic versus non-ischemic conditions, while the NRS scale was the least
effective at showing changes in pain. Pain increases during exercise on the MPQ and

∆

Faces scales, indicating that exercise induces pain independent of ischemia, Figure 3.7.

Figure 3.6: Trends in ∆NRS Pain by Treatment Type, Phase, and Ischemia. NRS
pain increases during occlusion and remains elevated during recovery for every treatment
type. When ischemia is induced, NRS pain increases more during occlusion. Values are
shown as means ± SE. *p ≤ 0.001 for ∆pain vs. phase, treatment, & ischemia.
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A

*

B

*

C

*

Figure 3.7: Trends in ∆Pain by Phase and Ischemia. ∆Pain is greatest during the
occlusion phase with ischemia as shown by the A. MPQ scale, B. NRS, and C. Faces
scale. The other 2-way interactions for ∆pain between ischemia and phase have different
trends across the different scales. Values are shown as means ± SE. *p ≤ 0.001 for ∆pain
vs. phase & ischemia.

While the NRS and Faces scale show no differences in ∆pain within the exercise
and recovery phases (p ≥ 0.05), there are different trends in directionality between the
two scales. According to the NRS, pain trends toward a decrease during the exercise
phase, increases during the occlusion phase, and trends toward an increase in the
recovery phase. In contrast, the Faces scale trends toward an increase in pain for all three
phases. The NRS model is only able to explain 33% of the variability in change in
ischemic pain (R2 = 0.33), indicating that it has little predictive power. The Faces scale is
able to explain 61% of the variability (R2 = 0.61), and for this reason only the MPQ and
Faces scales are used for further analysis.
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3.5.4 Change in Vascular Resistance associated with Change in Pain
To test the hypothesis the analgesic effect is dependent upon decreases in vascular
̅̅̅̅ and ∆pain is analyzed for each experimental
resistance, the relationship between ∆𝑉𝑅
phase, treatment type, and ischemic condition, Appendix O, Table 3.C.
As expected, ischemic conditions during the occlusion phase invoke a strong
̅̅̅̅ and ∆pain, Figure 3.8A. However, during the exercise
positive relationship between ∆𝑉𝑅
̅̅̅̅ decreases as ∆pain
phase, there is a slightly negative relationship such that ∆𝑉𝑅
increases. This again suggests an exercise-mediated pain pathway is present and operates
̅̅̅̅ trends to increase more
independently of ischemic pain mechanisms. Interestingly, ∆𝑉𝑅
rapidly in relation to pain with IFC treatment as compared to TENS and placebo, though
̅̅̅̅ and ∆pain between
there are no significant differences in the relationship between ∆𝑉𝑅
the three treatment types, Figure 3.8B.
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A
∆

B
∆

Figure 3.8: Effects of Ischemia, Phase, and Treatment Type on the Relationship
̅̅̅̅ . Ischemia and pain influence the relationship between
between ∆MPQ Pain and ∆𝑉𝑅
̅̅̅̅ . A. ∆MPQ Pain and Ischemia. B. ∆MPQ Pain and Treatment.
∆pain and ∆𝑉𝑅

3.6 DISCUSSION
The main goal of this study was to investigate trends in increased blood flow and
decreased vascular resistance and pain associated with neurostimulation under ischemic
conditions, possibly due to a decrease in sympathetic tone and increase in C fiber
inhibition mediated by Aβ fiber activation. We could not detect any significant
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hyperemic or analgesic effects of either TENS or IFC as predicted, though interestingly
neurostimulation tended to increase vascular resistance during acute ischemia as well as
under non-ischemic conditions after static exercise.
In a similar study in healthy young subjects similar to our study population, TENS
increased blood flow and lowered vascular resistance in the calf [32]. The discrepancy
between the results of the two studies is most likely not due to statistical power; our study
had 45 replicates while the comparator study had 12. Rather, the different results may be
due to differences in blood flow measurement techniques, with calf blood flow measured
using venous occlusion plethysmography (VOP) as compared to cutaneous palmar blood
flow measured using laser Doppler flowmetry (LDF) in our study. Plethysmography is a
volume-based measurement, while laser Doppler signals are recorded in arbitrary
Perfusion Units (PU) based on a motility standard that does not take tissue volume into
account [75]. Thus, VOP may capture whole limb blood flow while LDF is limited to
cutaneous perfusion.
Indeed, the relationship between LDF and VOP blood flow measurements during
exercise is nonlinear [76]. LDF and VOP measurements are similar during early
cutaneous vasodilation, but in later phases LDF values level off while VOP perfusion
measurements increase. Furthermore, differences tissue composition between subjects
can affect blood refractivity, introducing inter-subject type II error in LDF measurements
[77], and therefore between-subject variability must be controlled for by including
subject in the data analysis. Although measurements taken from both techniques reflect
changes in perfusion, the magnitudes of changes in blood flow during active vasodilation
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would not correlate. Thus, it is possible that neurostimulation had a greater hyperemic
effect than measured.
We hypothesized that neurostimulation inhibits sympathetic vasoconstriction by
inhibiting NE release at peripheral sympathetic nerve terminals. Therefore,
neurostimulation ought to affect whole-limb blood flow, not just cutaneous blood flow.
To more accurately assess whole-limb hemodynamic responses, future researchers should
consider using an alternative system such as VOP to measure tissue perfusion rather than
LDF. However, since VOP is too invasive to be feasible for use at Cal Poly, ultrasonic
blood flow monitoring may serve as an effective alternative. Ultrasound techniques are
used to detect early stages of atherosclerosis in peripheral arteries by measuring real-time
blood velocities [78]. Similarly to LDF, ultrasound blood flow profiles will decrease
during occlusion and can be used to screen for ischemic conditions. However, ultrasound
blood flow measurements are more accurate than those taken with LDF systems [79].
Hand-held ultrasound blood flow measurement systems are affordable within the Cal
Poly MEDITEC budget and are feasible for student use [80].
Since our blood flow measurement system may have been limited to cutaneous
blood flow, neurostimulation may have a more profound effect on vascular tone
throughout the forearm tissue than captured by our measurements. However, trends in
vascular resistance and pain were observed with neurostimulation in response to
ischemia, Table 3.2.
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Table 3.2: Experimental Trends in Hemodynamic Factors and Pain during
Recovery.

Expected Outcome

Placebo

TENS

IFC

PECO- PECO+ PECO- PECO+ PECO- PECO+

Heart Rate

↓

-

↓

-

-

↓

Skin Temperature

↑

↑

↑

↑

↑

↑

Mean Blood Pressure

-

↓

↓

↓

↓

↓

Local Blood Flow

↑

↑↑

↑

↑↑

↑

↑↑

Contralateral Blood Flow

↑

↑

↑

↑

↑

↑

Vascular Resistance

↓

↓

-

↓

-

↓

Ischemic Pain

↑

↑

-

↑

-

↑

3.6.1 Change in Blood Flow
As expected, local tissues experienced a rapid increase in blood flow following
occlusion due to the local release of vasodilator metabolites during ischemia. This
phenomenon, known as reactive hyperemia, was observed for all three treatment types
during the recovery phase. In addition, blood flow increased during exercise as expected,
Figure 3.3. Compression of intramuscular arterioles during exercise results in the release
of endothelial-derived vasodilator metabolites that competitively inhibit the effects of NE
and thus inhibit sympathetic vasoconstriction in active tissues [81]. Forearm blood flow
is higher at 30% than at 10% maximum voluntary contraction in the forearm following a
2 minute isometric contraction [82], indicating that SNS activity can be prevented by
low-intensity exercise. These results followed the same general trends across all groups,
Appendix N, with very little between-subject variability, Appendix P.
We hypothesized that an additional vasodilatory mechanism independent of
reactive hyperemia and functional sympatholysis would be present in vessels undergoing
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neurostimulation. Transcutaneous neurostimulation may activate peripheral α-2
adrenergic receptors [73], inhibiting norepinephrine release and decreasing local
sympathetic tone. However, neurostimulation did not have its expected effect. Both
TENS and IFC had a general trend towards decreased blood flow in both ischemic and
non-ischemic conditions such that ischemia was more severe during occlusion while
reactive hyperemia was dampened.
It is possible that we did not see an increase in blood flow associated with
neurostimulation if there was no electrical α-2 adrenergic activation during exercise or if
metabolic vasodilation during exercise amplified the hyperemic response and
overwhelmed any additional increase in blood flow caused by electrical α-2 adrenergic
activation. In order to distinguish between these two possibilities, we must include a nonexercise group in future studies and compare changes in blood flow with and without
neurostimulation between the exercise and non-exercise groups.
Although a statistically significant difference eluded our study, the application of
TENS and IFC to the ganglions can increase peripheral vasodilatory capacity and reduce
blood pressure at the end of exercise in young healthy subjects [39, 32, 52], though there
are conflicting reports on their efficacy. The mechanisms behind these observed
hemodynamic trends is still unclear, though the blood flow measurement methods of
VOP and ultrasound, respectively, may have introduced inconsistencies when comparing
studies.
As stated previously, it is possible that the changes in cutaneous blood flow
observed using LDF were not reflective of changes in whole-limb perfusion associated
with neurostimulation. It is also possible that the increase in local blood flow regardless
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of treatment type may be linked to metabolic vasodilator substances released during the
isometric handgrip exercise. To isolate the effects of exercise from occlusion and
neurostimulation on hyperemia, future studies ought to have both an exercise group and a
non-exercise group in addition to blocking by treatment type (TENS, IFC, and placebo).
If blood flow is reduced in non-exercise groups as compared to exercise groups, then
exercise-induced vasodilation would indeed be a compounding effect.
However, this explanation for the negative blood flow results cannot account for
the latency of the inhibitory effect of neurostimulation on exercise hyperemia when the
occlusion was not applied. Previous evidence suggests that pre-treatment with TENS has
no immediate effect on local blood flow but improves exercise tolerance at later time
points [48]. Although the mechanism is unclear, it is possible that latent effects of both
TENS and IFC may be associated with latencies in cellular activation. Transcutaneous
stimuli have to travel through layers of skeletal muscle and connective tissue before they
reach sympathetic neuron cell bodies in the ganglion, and signal impedance may be a
time-dependent function of tissue conductance [83]. Therefore, it is possible that the
stimuli did not sufficiently activate SNS neurons until later time points. Future studies
may consider including a 5 minute pre-conditioning phase before beginning the trial in
order to allow for the stimuli to overcome surface impedance and penetrate the ganglion.
3.6.2 Change in Vascular Resistance
The trends observed in the blood flow responses are reflected in the vascular
̅̅̅̅ as expected, though interestingly IFC
resistance responses. Occlusion increases ∆𝑉𝑅
̅̅̅̅ during recovery while TENS tends to increase ∆𝑉𝑅
̅̅̅̅ as well, Table 3.5.
increases ∆𝑉𝑅
Although these results are opposite to our original hypothesis that neurostimulation
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̅̅̅̅, it does suggest that the hemodynamic effects of
increases blood flow and decreases ∆𝑉𝑅
IFC may be more exaggerated than those of TENS as we predicted. Furthermore, both
̅̅̅̅ under non-ischemic conditions after static exercise, though
TENS and IFC increase ∆𝑉𝑅
during recovery this effect is diminished as reactive hyperemia takes over following the
̅̅̅̅ is so much greater in
acute ischemic event. However, the effect of occlusion on ∆𝑉𝑅
̅̅̅̅ associated with either
magnitude than the effect of TENS or IFC that changes in ∆𝑉𝑅
form of neurostimulation could be considered clinically insignificant.
̅̅̅̅ associated
One possible explanation for why we did not see a decrease in ∆𝑉𝑅
with neurostimulation during acute ischemia as predicted is that peripheral α-2 adrenergic
activation via electrical stimulation is affected by hypoxic conditions. As previously
mentioned, electrical stimulation activates α-2 adrenoceptors, disrupting N-type calcium
current in sympathetic nerve terminals and inhibiting the release of norepinephrine, a
known vasoconstrictor. However, without sufficient blood flow, normal functioning of α2A receptors may be disrupted. For example, forebrain ischemia decreases α -2A receptor
binding in the rat hippocampus [84]. A similar event may be occurring in α-2A receptors
at the ganglion or at the synapse with smooth muscle cells following peripheral occlusion
in healthy young humans, though the mechanism is not clear.
Although we postulated that electrical stimuli have an inhibitory effect on
sympathetic signal transmission in Aβ fibers, a second possible explanation for the
observed inhibition of vasodilation associated with neurostimulation is that TENS and
IFC actually activated peripheral SNS neurons. To our knowledge there are no
comparative studies with published data indicating increased sympathetic vascular tone
associated with ganglial stimulation; however, TENS treatment has been used to activate
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the sympathetics in healthy humans [85], and since the somas of efferent SNS neurons
are located in the same ganglia as the somas of efferent Aβ fibers, it is possible that
transcutaneous stimulation applied at the ganglia activated efferent vascular SNS fibers
as opposed to efferent Aβ fibers and ultimately increased peripheral sympathetic
vasoconstriction.
3.6.3 Change in Pain
Pain is present throughout the experimental protocol regardless of phase, ischemic
conditions, or the type of neurostimulation applied, Figure 3.6. The MPQ scale
quantified the greatest magnitude of ∆pain during the exercise and occlusion periods, and
the Faces scale corroborates a positive ∆pain during exercise and occlusion as well as
during the recovery period, Figure 3.7. These results were the same across TENS, IFC,
and placebo treatments both with and without PECO and therefore do not support our
hypothesis that transcutaneous neurostimulation decreases ischemic pain.
There is a general consensus that neurostimulation, including TENS and IFC,
attenuates both chronic and acute ischemic pain [32, 62, 64, 66, 37]. However, the onset
and duration of analgesia may vary considerably between patients [37], and the same
protocol may have different degrees of antinociception in acute experimental pain
compared with chronic clinical pain [38]. There is also conflicting evidence indicating
that neurostimulation does not have a significant analgesic effect on this type of pain. IFC
and TENS treatments have shown no differences in analgesia as compared to
placebo during ischemic-induced pain tests utilizing the submaximal tourniquet technique
(similar to our study) and the cold pressor technique. Furthermore, 50 Hz and 100 Hz
TENS treatments have shown no differences in analgesia as compared to IFC treatments
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at the same frequency [49, 68, 65, 86]. Therefore the results from our study may be a true
negative, as opposed to a false negative, and similarly substantiate the observed nonsignificance of transcutaneous neurostimulation on acute experimental pain.
One possible explanation for the inability of subjects to detect a cessation in pain
is that that cytokines accumulated during the static handgrip exercise and caused pain.
While our study was not the first to involve exercise, more than half of our subjects
gripped above 30% maximal volumetric contraction and did not adequately decrease their
grip strength when instructed. Therefore, it is possible that our subjects experienced
greater microdamage to their skeletal muscle tissues and had higher concentrations of
algesic cytokines, including arachidonic acid (AA). AA is metabolized into
prostaglandin, which inhibits potassium efflux from nociceptors via a G protein, protein
kinase A cascade. The sensitized peripheral nociceptors transmit afferent signals to the
CNS which are interpreted as pain [87]. Although participants only applied 30% of their
maximum handgrip force, the exercise intensity and duration was sufficient to introduce
microdamage to the tissues [81, 82]. Analgesic cytokines from the exercise phase may
have remained un-metabolized in the tissues long enough to induce pain during the
occlusion and recovery phases as well. Therefore, dynamic exercise may be preferable to
static exercise for the purpose of our study in order to decrease the buildup of metabolic
byproducts.
It is also possible that summation of afferent exercise and ischemic pain signals
caused an overall increase in pain. Gate Control Theory postulates that TENS attenuates
nociception by stimulating Aβ fibers parallel to C fibers responsible for transmitting pain
signals to the brain [41]. However, the Central Summation Theory proposes that
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summation of pain may overwhelm the integration center in the thalamus, resulting in
increased pain [88]. Therefore, the summation of ischemic and exercise-induced pain
may cause an overall increased pain sensation regardless of Aβ fiber activation via
neurostimulation. Similar to isolating exercised-induced hyperemic effects, incorporating
a non-exercise group in future studies would help isolate the effect of exercise from
occlusion and neurostimulation on pain. If pain is reduced in non-exercise groups as
compared to exercise groups, then exercise-induced pain would indeed be a compounding
effect.
3.6.4 Change in Vascular Resistance associated with Change in Pain
̅̅̅̅ and pain
We hypothesized that electrical activation of Aβ fibers would reduce 𝑉𝑅
via parallel mechanisms. As expected, painful ischemic conditions during the occlusion
̅̅̅̅ and ∆pain, Figure 3.8A.
phase invoke a strong positive relationship between ∆𝑉𝑅
Graded increases in ischemic pain are associated with graded elevations in
forearm vascular resistance [89]. This coordination suggests that changes in pain and
vascular tone may be mechanistically linked, possibly due to a stress response. When the
brain detects a painful stimulus, the hypothalamus signals the adrenal glands to release
vasoconstrictive signaling molecules such as adrenaline and NE as part of the “flight or
fight” response. We see evidence of this phenomenon in how HR tended to decrease over
the course of each experimental trial, Appendix M, Figure III.C. Therefore we would
expect that vascular resistance would increase in response to an increase in pain.
Interestingly, while there are no significant differences in the relationship between
̅̅̅̅ and ∆pain between the three treatment types, ∆𝑉𝑅
̅̅̅̅ trends to increase more rapidly in
∆𝑉𝑅
relation to pain with IFC treatment as compared to TENS and placebo, Figure 3.8B. This
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indicates that subjects receiving IFC treatment experience increased vascular resistance in
response to a painful stimulus. To our knowledge, there is no evidence to date that TENS
̅̅̅̅, though the
and IFC have a different effect on the relationship between pain and 𝑉𝑅
differences in the trends observed in our study warrant further investigation with a larger
sample size. We predicted that our clinical study only needed 45 subjects per treatment
group to see a 10% decrease in VR and pain associated with neurostimulation, assuming
that the ΔVR and Δpain values observed for the placebo, PECO- group in pilot study IV
were valid control measurements. However, it is possible that the true between-subject
and within-subject variability associated with our study design are higher than were
sampled from pilot study IV, as the student volunteers during the pilot study were
homogenous in their age, ethnicity, and physical fitness levels. Therefore, increasing our
sample size to 100 subjects would double the predictive power of this study and may
increase our ability to observe changes in VR and pain associated with neurostimulation.
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CHAPTER 4: SUMMARY

4.1 SYNOPSIS
Peripheral arterial occlusive disease (PAOD) is a pervasive disease characterized
by impaired metabolic vasodilation in the peripheries. While intermittent claudication
symptoms develop in symptomatic patients, limb ischemia develops in all cases as the
disease progresses. The current gold standard of treatment is a combined drug and
surgical intervention involving statins, antihypertensive drugs, angioplasty, and stenting.
While this approach addresses the impaired blood flow and pain symptoms associated
with PAOD, there are often adverse side effects and restenosis.
Neurostimulation may provide a much-needed innovative treatment option for
PAOD, as it has a known analgesic effect on both acute and chronic pain and may also
increase blood flow. Electrical activation of afferent Aβ fibers, either in the periphery or
near the ganglia, inhibits both pain-signal transmission from afferent C fibers and
norepinephrine release at sympathetic nerve terminals. The Gate Control Theory explains
how Aβ fibers activate an inhibitory interneuron in the dorsal horn of the spinal cord that
synapses with ascending spinothalamic (ST) neurons, effectively dampening the pain
signal to the brain. Simultaneously, suppression of the ST neurons may result in
decreased metaboreflex control as systemic sympathetic vasoconstriction is reduced and
mean blood pressure decreases. Aβ fiber activation is also thought to activate α-2
adrenoceptors on primary afferent neurons along the same dermatome, resulting in
suppressed sympathetic tone and an increase in local blood flow. Ultimately, electrical
stimulation may decrease local vascular resistance (VR), Figure 1.7.
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The focus of our study was to optimize methods and perform a small-scale
clinical study for investigation of hemodynamic and pain responses to neurostimulation
during an ischemic event in otherwise healthy subjects. We hypothesized that
transcutaneous electrical neurostimulation (TENS) and interferential current (IFC)
treatments applied at the C7 and T4 ganglia would result in decreased pain and local
vascular resistance in the palms and that IFC may have a greater analgesic and hyperemic
effect than TENS due to differences in stimulus current waveforms.
Unfortunately, our findings did not directly support either hypothesis. We found
no significant analgesic or hyperemic effects during or following acute ischemia; rather,
we saw trends indicating that TENS and IFC increase pain and VR under both ischemic
and non-ischemic conditions. Interestingly, IFC increased VR under acute ischemic
conditions while TENS had a lesser effect. We also observed a greater increase in VR
correlated with an increase in pain with IFC as compared to TENS, indicating that the
out-of-phase sinusoidal waveform characteristic of IFC may more readily overcome skin
impedance and have a greater effect on sympathetic tone as predicted.
4.2 FUTURE WORK
Considering the outcome of this study, we would propose several changes to the
study design that may help to establish clearer conclusions from the data. Future
researchers should consider replacing the laser Doppler flowmetry blood flow
measurement system with an ultrasound system as it is both feasible for use by students
and more accurate at measuring whole-limb perfusion [79]. It would also be
advantageous to recruit study participants from a more diverse age range (18-25 years
versus 50+ years) and lifestyle (athletic versus sedentary) by targeting recruitment to
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professors and student athletes in addition to the general student population, as a healthy
young sample population is not reflective of the general PAOD patient population [3].
Many participants were anxious about using neurostimulation for the first time, as
evidenced by a general trend towards decreased heart rate over the course of the session,
Appendix M, Figure III.C. Incorporating an introductory trial run with each participant
a day or more prior to the study sessions may allow for less stress-induced sympathetic
response during the data collection. Furthermore, including a non-exercise group will be
necessary to isolate the effects of exercise from occlusion and neurostimulation on
hyperemic and analgesic trends.
It may also be interesting to further investigate the effects of paresthesia on trends
in hyperemia and analgesia. Paresthesia introduced significant variability to the pain data
as it was often perceived by the participants as an unusual or irritating sensation during
testing, Appendix P. If the stimulus intensity was set to a subparesthesia level,
sympathetic vasoconstriction due to the stress response and non-painful stimuli
incorporated into the self-reported pain scores may diminish, possibly resulting in less
noise in the blood flow and pain data and more pronounced hyperemia and analgesia
associated with neurostimulation. Furthermore, amplifying the baseline pain signal may
also improve the signal-to-noise ratio. While the Cal Poly Human Subjects Committee
approval only extends to 180 mmHg of pressure on the forearm for the submaximal
tourniquet technique, it is possible that moving the site of occlusion to the upper arm may
be more painful for most people than an equivalent pressure on the forearm. Interestingly,
the amount of pain induced by the submaximal tourniquet technique in our study was less
than that captured in comparator studies using a similar numeric rating scale; therefore,
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an alternative ischemic pain method should be considered. The cold pressor test may also
be used to test the analgesic and hyperemic effects of neurostimulation and may provide a
greater painful stimulus that the tourniquet technique [65, 68].
Finally, incorporating a measurable control for skin surface electrode impedance
may be important for standardizing treatment across subjects. While future studies ought
to consider including a 5 minute pre-conditioning phase in order to control for the latent
effects of transcutaneous stimulation and allow time for the stimuli to overcome surface
impedance, slight differences in electrode configuration and tissue conductance between
patients can alter the electric field distribution and thereby the depth and selectivity of
neural activation [83]. Although we attempted to control the shape and depth of the
electric field by standardizing electrode placement, a more accurate approach may be to
use a multimeter to quantitatively assess surface impedance. While most
electromyography (EMG) units have a built-in impedance sensor to direct electrode
placement, commercially available TENS units do not [90]. Incorporating a similar user
feedback mechanism into future TENS unit designs would be desirable.
Although our study was not able to find significant evidence that IFC has a
greater analgesic or hyperemic effects than TENS, nor that transcutaneous
neurostimulation in general had such effects, further characterization of the different
stimulus waveforms may provide great insight into extracellular electrical control of
vascular tone.
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APPENDICES
Appendix A: Informed Consent Form
INFORMED CONSENT TO PARTICIPATE IN A RESEARCH PROJECT:
“The Effects of Transcutaneous Electrical Neurostimulation on Analgesia and
Peripheral Perfusion”
A research project on peripheral blood flow and ischemic pain is being conducted
by Leah Schafer and Kaylee Keck in the Department of Biomedical Engineering at Cal
Poly, San Luis Obispo. The purpose of the study is to measure changes in blood flow,
heart rate, and blood pressure due to the application of electrical neurostimulation.
You are being asked to take part in this study by first filling out a short medical
history questionnaire. Questions marked with an asterisk (*) are required, but any others
you do not wish to answer may be omitted. These questions are directly related to your
safety. During each treatment session, you will be hooked up to a neurostimulation
device that will be attached to your upper back with electrodes, a blood flow
measurement system using skin probes on the upper arms, a respiration belt wrapped
around your midsection, and a blood pressure cuff applied to each arm. Appropriate
clothing should be worn to ensure proper placement of the electrodes on your upper back.
Prior to the treatment session, you will be asked to not consume caffeine for up to 12
hours before the session in an effort to minimize caffeine’s effects on blood flow. Once
the session begins, you will be asked to squeeze a handgrip force measurement device for
a short period of time. You will experience electrical stimulation from the attached
electrodes, which you may feel as a warm, tingling sensation on your back. Your
participation will involve 6 sessions, with a 10-minute break (5 breaks) in between each
session, for a total of 2 hours on one day. In some of these sessions, the neurostimulation
device will be hooked up to you, but no current will be applied, as in you will not feel
any sensation on your back. This will be randomized. Please be aware that you are not
required to participate in this research and you may discontinue your participation at any
time without penalty.
The possible risks associated with participation in this study include pain due to
temporarily induced ischemia i.e. insufficient blood flow to the tissue, skin irritation from
the application of skin probes and electrodes, and possible discomfort and/or stress from
gripping the hand force measurement device. If your personal pain tolerance threshold is
reached at any point, you may discontinue your participation immediately. If you should
experience residual pain or tingling after the duration of the experiment or an allergic
reaction at the site of the probes or electrodes, please be aware that you may contact Cal
Poly Health and Counseling Services, located in building 27, at (805) 756-1211 for
assistance.
Your confidentiality will be protected by recording your medical history, age,
gender, height and weight on a document with a corresponding code. This document will
be kept as a hard copy only and separate from the corresponding list of codes. Your
information will only be accessible to the researchers in this study. If the results of the
study are published, any identifying information will be omitted. The incentive associated
with this study is a benefit in the form of a $25 Visa gift card to those that choose to
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participate and agree to the caffeine restrictions. In the case that you choose to
prematurely discontinue your participation due to possible discomfort and/or stress,
monetary compensation will still be provided. You may only volunteer once for this
study. Depending on the outcome of the study, this could become an additional treatment
method for individuals with ischemic pain.
If you have questions regarding this study or would like to be informed of the
results when the study is completed, please feel free to contact Leah Schafer at (530) 3545061 or Dr. Trevor Cardinal at (805) 756-6244. If you have concerns regarding the
manner in which the study is conducted, you may contact Dr. Steve Davis, Chair of the
Cal Poly Human Subjects Committee, at (805) 756-2754, sdavis@calpoly.edu, or Dr.
Dean Wendt, Dean of Research, at (805) 756-1508, dwendt@calpoly.edu.
If you agree to voluntarily participate in this research project as described, please
indicate your agreement by signing below. Please keep one copy of this form for your
reference, and thank you for your participation in this research.

______________________________________________________________
Signature of Volunteer

Date

______________________________________________________________
Signature of Researcher
Date
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Appendix B: Medical History Questionnaire

MEDICAL HISTORY
*= Required
General Information
Participant:
*Name:___________________________________________________________
*Email: __________________________ Contact phone number: _____________
*Dominant Hand: □ Right

□ Left

Age: _________________________________
Height: _______________________________
Weight: _______________________________
Sex:
□ Male

□ Female

Women only answer the following:
*Are you currently pregnant?
□ Yes
Are you currently breast-feeding? □ Yes

□ No
□ No

Men and women answer the following:
*Have you consumed caffeine in the last 12 hours? □ Yes
□ No
*Have you exercised to at least 50% of your maximum heart rate (moderate
exercise) in the last:
48 hours?
□ Yes
□ No
12 hours?
□ Yes
□ No
List any prescription medications you are currently taking:
__________________________________________________________________
Do you have any implantable electrical devices (pacemaker, implantable
cardioverter defibrillator, etc.)?
□ Yes

□ No

If yes, please list: ________________________________

In the past two months, have you experienced any major injury or significant
trauma to your arms or upper back?
□ Yes
□ No
If yes, please
describe: _________________________________________________________
[over]
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Past Medical History

Have you experienced any of the following:
Yes No
□ □ *Dermatitis/eczema (inflammation of the skin)
□ □ *Chronic pain or tingling sensations in your limbs
□ □ *Syncope (fainting)
□ □ *Epilepsy or seizures
□ □ Heart attack
□ □ High blood pressure (hypertension)
□ □ Rheumatic Fever
□ □ Heart murmur (abnormal heart sound)
□ □ Arrhythmia (irregular heartbeat)
□ □ Diseases of the arteries (peripheral artery disease, coronary artery disease)
□ □ Varicose veins (twisted, enlarged veins)
□ □ Diabetes or abnormal blood sugar
□ □ Phlebitis (inflammation of the veins)
□ □ Stroke
□ □ Anemia (low red blood cell count)
Smoking
Have you ever smoked tobacco?

□ Yes

□ No

If yes, how long did you smoke/how long have you been smoking?__________
How frequently did/do you smoke? ___________________________
Drinking
On average, do you drink more than 1 alcoholic beverage per day (women)/ 2
alcoholic beverages per day (men)?
□ Yes
□ No
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Appendix C: W9 Tax Form
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Appendix D: Cal Poly Human Subjects Committee Approval Form

All Cal Poly faculty, staff, and student research with human subjects, as well as other research
involving human subjects that is conducted at Cal Poly, must be reviewed by the Cal Poly
Human Subjects Committee for the protection of human subjects, the researchers, and the
University. Human subjects research is defined as any systematic investigation of living human
subjects that is designed to develop or contribute to generalizable knowledge. While the ethical
guidelines for research are applicable to classroom activities, demonstrations, and assignments,
the Human Subjects Committee does not review classroom activities unless data will be collected
and used in a systematic investigation.
Researchers should complete all items on this approval form and submit it, along with a research
protocol (containing the information detailed in Guidelines for Human Subjects Research
Protocol), to the Office of Research and Economic Development (Debbie Hart, Bldg. 38, Room
154). Please feel free to attach an additional page if your responses to any of the items require
more space. Your answers to the items on this form, as well as the research protocol, should be
typed. The Committee will make every effort to respond to your submission within two to four
weeks. Committee approval should be received prior to contacting prospective subjects and
collecting data. Please read carefully Cal Poly's Policy for the Use of Human Subjects in
Research prior to completing this application.

If you require assistance in completing this form,
contact the Office of Research and Economic Development at (805) 756-1508.
1. Date:

4/12/15

3. Type of Research:
x Senior project
x Master’s thesis
Faculty research
Other:

2. Title of Research Project:
The Effects of Transcutaneous Electrical
Neurostimulation on Analgesia and Peripheral
Perfusion

please explain

4. Name(s) of Researcher(s)
Principal Investigator:
Leah Schafer
Department or other affiliation:
Phone:
Position:

5303545061

Email:

Faculty
Other:

Additional Researcher:

x

Position:

5599205233
Faculty

lischafe@calpoly.edu

Student

please explain
Kaylee Keck

Department or other affiliation:
Phone:

Biomedical Engineering

Biomedical Engineering
Email:
x
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kkeck@calpoly.edu

Student

Other:

please explain

Additional Researcher:
Department or other affiliation:
Phone:
Position:

Email:
Faculty

Student

Other:
please explain
Any additional researchers involved in the project should be listed with the descriptive
information requested above on a separate sheet.
5. Faculty Advisor (if applicable)
Name: Trevor Cardinal, Ph.D.

Email:

Department or other affiliation: Biomedical Engineering
Other thesis committee members if the research is a thesis:
Name: Stuart Rosenberg
Email:
Department or other affiliation:
Name:

Melanie Goodman, Ph.D.

Department or other affiliation:
Name:

St. Jude Medical

Department or other affiliation:

Phone:

St. Jude Medical
Biomedical Engineering

8184933629

mgoodman2@sjm.co
Phone:

Email:

8057566244

srosenberg@sjm.com
Phone:

Email:

Kristen O’Halloran Cardinal, Ph.D.

tcardina@calpoly.edu

9725264683

kohallor@calpoly.edu
Phone:

8057562675

6. Is there an external funding source for the project:
x Yes, and the source is:
St. Jude Medical MEDITEC
No
7. Is this a modification of a project previously reviewed by Cal Poly’s Human Subjects
Committee?
x Yes, and the approximate date of the last review was:
2/11/15
No
8. Estimated duration of the project:
Starting date:
5/1/15

Completion date:

7/1/15

9. Describe any risks (physical, psychological, social, or economic) that may be involved.
See Specific Ethical Criterion #1 in Policy for the Use of Human Subjects in Research for a description of the
types of risks.

The participant will experience ischemic pain i.e. pain resulting from insufficient blood flow
to a tissue as a result of acute forearm occlusion by a sphygmomanometer at 180 mmHg for 3
minutes. The participant may experience slight skin irritation with the application of skin
probes and electrodes. The participant may experience some discomfort during static
handgrip exercise for 3 minutes.
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10. Indicate what measures will be taken to minimize risks. See Specific Ethical Criterion #1 in
Policy for the Use of Human Subjects in Research for a discussion of strategies for minimizing risks.

The temporarily induced ischemic pain will be assessed every minute using Numeric Rating
and Faces pain scales similarly to related published research methodologies. Ischemia will not
be held for over 3 minutes at 180 mmHg in accordance with clinical instructions for use. If
pain intensity reaches a subject’s personal pain tolerance threshold, the trial will be
immediately terminated. For skin irritation k a topical antihistamine (Benadryl) may be
applied to the area. Handgrip exercise will not exceed 3 minutes.
11. Explain how subjects' confidentiality will be protected. See Specific Ethical Criterion #5 in
Policy for the Use of Human Subjects in Research for a discussion of strategies for minimizing risks.

Participant information will be recorded in terms of their medical history, age, gender, height,
and weight. This information will be recorded in a hard copy of the medical questionnaire
document with a corresponding code for each patient. These documents will be kept in Dr.
Trevor Cardinal’s locked office or in a locked drawer in the testing lab. All data recordings
will be stored electronically on the P.I.’s personal computer and accessible only to Leah
Schafer, Kaylee Keck, and Dr. Cardinal.
12. Describe any incentives for participation that will be used. See Specific Ethical Criterion #2
in Policy for the Use of Human Subjects in Research for a discussion of the use of incentives in research.

A $25 Visa gift card will be offered to participants that agree to the caffeine restrictions. In the
case that a participant chooses to prematurely discontinue their participation due to possible
discomfort and/or stress, monetary compensation will still be provided.

13. Will deception of subjects be involved in the research procedures?
x
Yes*
No
*If so, explain the deception and how it will be handled. See Specific Ethical Criterion #3 in
Policy for the Use of Human Subjects in Research for a discussion of the use of deception in research:

The study is designed to be single-blinded such that the participant does not know whether
they are in a placebo (control) trial or treatment trial. The control trial will involve attaching
neurostimulation electrodes just as in the treatment trial; however, no electrical stimulation
will occur during control. This is necessary to determine if the neurostimulation itself is
actually causing the changes witnessed.

14. Type of review requested:
Exempt from further review*
x
Expedited review
Full review
See Types of Review in Policy for the Use of Human Subjects in Research for a discussion of
the criteria for exempt, expedited, and full reviews.
*The research protocol submitted for a project presumed to be exempt may be abbreviated but should contain
sufficient information to support the conclusion that the project meets the criteria for exemption.
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Appendix E: Pilot Study Experimental Design Summary Presentation
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Appendix F: Protocol
I.

II.

Setup
1.
2.
3.
4.
5.
6.

Turn on the laptop.
Connect the power supply to PowerLab.
Connect the USB cable from PowerLab to the laptop.
Connect the respiration belt to Input 1 on the front panel of PowerLab.
Connect the Hand Dynamometer to Input 2 on the front panel of PowerLab.
Connect the power supply to the Laser Doppler Flow (LDF) system and turn it
on.
7. Connect the skin probes to Channels 1 and 2 on the LDF system.
8. Connect the BNC cables from the LDF system to Inputs 3 and 4 on the front
panel of PowerLab.
9. Turn on the PowerLab system.
10. Open LabChart on the laptop and open the customized settings file.
i. The raw breath signal in millivolts (mV), the respiratory rate in breaths
per minute (BPM), the handgrip force in Newtons (N), CBF 1 in
perfusion units (PU), and CBF 2 in PU should all be displayed in
LabChart at this point.
Application
1. Seat the participant in a chair with both arms supinated and gently resting on the
tray. Ensure that they are comfortable and properly positioned before continuing.
2. Apply the electrodes to the C7 and T4 vertebrae locations, approximately 3 cm to
the left and right of the vertebral column (Figure 1).†
3. Wrap the respiration belt around the participant’s chest, just below the xiphoid
process.
4. Attach the skin probe connected to Channel 1 of the LDF system to the left arm,
2 cm below the crease of the wrist.
5. Attach the skin probe connected to Channel 2 of the LDF system to the right arm,
2 cm below the crease of the wrist.
6. Wrap the cuff connected to the manual sphygmomanometer around the
participant’s left forearm, 2 cm below the crease of the elbow.
7. Wrap the cuff connected to the blood pressure monitor around the participant’s
right arm.
8. Instruct the participant to loosely grip the Hand Dynamometer in their dominant
hand.
9. Instruct the participant to squeeze the Hand Dynamometer as hard as possible for
a second or two, and then relax their grip.*
10. Determine Maximum Voluntary Contraction (MVC) by recording the average of
three handgrip trials and calculate 25% of MVC.

* Adapted from BMED 460 – “Muscle Stimulation Fatigue Student Protocol” by Trevor Cardinal
† Adapted from "Effect of transcutaneous electrical nerve stimulation on muscle metaboreflex in healthy young and older subjects." by
Vieira, et. al.
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Figure 1: TENS Electrode Placement at the C7 and T4 Regions*

III.

Treatment
1. Begin treatment according to assigned group code.†
2. Every minute, assess the intensity of the participant’s pain via the NPRS. In
addition, halfway through each interval of the treatment i.e. “baseline”,
“exercise”, “occlusion”, and “recovery”, record the participant’s blood pressure
and heart rate from the monitor.
3. Set the stimulation frequency to 100 Hz, pulse duration to 200 μs, and slowly
adjust the intensity to just above sensory threshold (no pain or muscle
contraction) by asking the participant when he/she begins to feel a strong, but
comfortable tingling sensation.
4. Begin 1 min metronome and instruct participant to verbalize his or her pain level
every min.
5. Begin 1.5 min metronome and collect BP & HR data every 1.5 min.
6. Begin recording baseline blood flow for 3 minutes at resting heart rate.
7. Place the hand dynamometer in the participant’s left hand. Instruct the participant
to perform a static handgrip exercise for 3 minutes at 25% MVC.
8. Five seconds before exercise completion, inflate the sphygmomanometer cuff to
180 mmHg.!
9. Maintain cuff inflation at 180 mmHg for 3 minutes, while still recording blood
flow.
10. Deflate the cuff immediately and record for 3 minutes.
11. Stop recording.
12. Insert comments for “baseline”, “exercise”, “occlusion”, and “recovery” at the
end of each interval.
13. Detach all equipment from the participant and wait at least 10 minutes before
beginning the next treatment.

* Adapted from "Effect of transcutaneous electrical nerve stimulation on muscle metaboreflex in healthy young and older subjects"
Vieira, et. al.
† Group codes: Placebo/PECO- (P-), Placebo/PECO+ (P+), TENS/PECO- (T-), TENS/PECO+ (T+), IFC/PECO- (I-), IFC/PECO+(I+)
!
Only if PECO+ group
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Appendix G: Sample of Data Master
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Appendix H: Numeric Pain Scale (NRS) and Faces Pain Scale
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Appendix I: Modified Short-Form McGill Pain and Paresthesia Questionnaire

102

Appendix J: Prediction Expression for Changes in Vascular Resistance
Prediction Expression:
log10(VR+10) = Average change in VR + Phase + Treatment + Phase*Treatment + Ischemia
+Phase*Ishcemia + Treatment*Ischemia + Phase*Treatment*Ischemia + Subject
Expanded Prediction Expression:

log10(VR+10) =
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Appendix K: Prediction Expression for ∆MPQ and ∆Faces Pain
∆Faces Pain:

∆MPQ Pain:
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Appendix L: Prediction Expression for Changes in Vascular Resistance and Pain

Prediction Expression:
log10(VR+10) = ̅̅̅̅̅̅
∆𝑉𝑅 + Phase + Ischemia + Treatment + MPQ + Phase*MPQ +
Ischemia*MPQ + Treatment*MPQ + Subject

Expanded Prediction Expression:
log10(VR+10) =
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Appendix M: Mean Changes in Hemodynamic Factors and Pain for Treatment
Type by Ischemia and Phase

A

B
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C

D

Figure 3.9: Mean Changes in Non-Significant Hemodynamic Factors for Treatment
Types by Ischemia and Phase. A. Change in contralateral blood flow. B. Change in
local blood flow. C. Change in mean arterial pressure (MAP). D. Change in Skin
Temperature. E. Change in heart rate. Values are shown as means ± SE.
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A

B
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Figure 3.10: Mean Changes in Pain for Treatment Type by Ischemia and Phase. A.
Change in Faces pain. B. Change in NRS Pain. C. Change in MPQ Pain. Values are
shown as means ± SE.
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Appendix N: Hemodynamic and Pain Trends during Exercise, Occlusion, and
Recovery

A

B
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D
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E

F

Figure 3.11: Trends in Hemodynamic Factors during Exercise, Occlusion, and
Recovery Phases. A. Local blood flow. B. Contralateral blood flow. C. Skin
temperature. D. Heart rate (HR). E. Mean blood pressure (MBP). F. Vascular resistance
(VR). Absolute changes in hemodynamic factors during the static handgrip exercise, after
exercise with (PECO+, gray lines) and without (PECO-, black lines) circulatory
occlusion, and during recovery in healthy young individuals with IFC (continuous lines),
TENS (dotted lines), and placebo (dashed lines). Values are shown as means ± SE.
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Figure 3.12: Change in Pain during Exercise, Occlusion, and Recovery Phases. A.
NRS pain. B. Faces pain. C. MPQ pain. Absolute changes in pain during the static
handgrip exercise, after exercise with (PECO+, gray lines) and without (PECO-, black
lines) circulatory occlusion, and during recovery in healthy young individuals with IFC
(continuous lines), TENS (dotted lines), and placebo (dashed lines). Values are shown as
means ± SE.
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̅̅̅̅ and Pain
Appendix O: Effects of Phase, Treatment Type, and Ischemia on ∆𝑽𝑹
Different levels of each dependent variable, i.e. the O, E, and R levels of the
̅̅̅̅ and ∆pain. These effects are denoted by
phase variable, have a different effect on ∆𝑉𝑅
the fixed effect coefficient α.
̅̅̅̅. The average ∆𝑉𝑅
̅̅̅̅
Table 3.3: Effects of Phase, Treatment Type, and Ischemia on ∆𝑉𝑅
predicted by the dataset is offset by a value α for different phases, treatment types, and
ischemic conditions. Using Tukey-Kramer’s for post hoc comparisons, levels that do not
̅̅̅̅ (p ≤ 0.01).
share a letter have different effects on ∆𝑉𝑅
Factor

p Value

Level

Tukey

Phase

<0.0001

O

A

Treatment Type

0.0005

<0.0001

<0.0001

Coeff

[µmHg/PU]
𝛼𝑂

+93.4

B

𝛼𝐸

-41.3

R

B

𝛼𝑅

-52.0

𝛼𝐼

+11.2

B

𝛼𝑇

+2.00

B

𝛼𝑃

-13.2

𝛼𝑃𝐸𝐶𝑂+

+37.0

𝛼𝑃𝐸𝐶𝑂−

-37.0

𝛼𝑂 𝛼𝑃𝐸𝐶𝑂+

+91.9

I

A

T

A

PECO+

A

PECOPhase*Ischemia

̅̅̅̅,
Effect on ∆𝑉𝑅

E

P
Ischemia

Fixed Effect

O,+

B
A

O,-

B

𝛼𝑂 𝛼𝑃𝐸𝐶𝑂−

-91.1

R,-

B

𝛼𝑅 𝛼𝑃𝐸𝐶𝑂−

+53.1

E,-

B

C

𝛼𝐸 𝛼𝑃𝐸𝐶𝑂−

+38.7

E,+

B

C

𝛼𝐸 𝛼𝑃𝐸𝐶𝑂+

-38.7

C

𝛼𝑅 𝛼𝑃𝐸𝐶𝑂+

-53.1

R,+
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Table 3.4: Effects of Phase and Ischemia on Change in Pain. The average pain
predicted by the dataset is offset by a value α for different phases and ischemic
conditions, while treatment type has no significant effect. Using Tukey-Kramer’s for post
hoc comparisons, levels that do not share a letter have different effects on change in pain
(p ≤ 0.01).
Factor

p value

Level

Tukey

Phase

<.0001

O

A

<.0001

Ischemia*

<.0001

Phase

O,+

A

[∆Faces Pain]

𝛼𝐸

+0.534

+0.0813

𝛼𝑅

-

-75.9

𝛼+

+0.606

+77.9

𝛼−

-0.606

-77.9

𝛼𝑂 𝛼+

+1.12

+121

B

-

[∆MPQ Pain]

+75.8

A

+

Effect, 𝛼

+1.02

C

R

Effect, 𝛼

𝛼𝑂
B

E

Ischemia

Effect Coeff

E,+

B

𝛼𝐸 𝛼+

+0.513

+59.5

E,-

B

𝛼𝐸 𝛼−

-0.513

-59.5

R,-

B C

𝛼𝑅 𝛼−

-

+61.4

R,+

B C

𝛼𝑅 𝛼+

-

-61.4

O,-

C

𝛼𝑂 𝛼−

-1.12

-121

̅̅̅̅. The relationship between ∆𝑉𝑅
̅̅̅̅ and MPQ pain is
Table 3.5: Effects of Pain on ∆𝑉𝑅
dependent on the interactions between phase and treatment type effects, α, and a slope
̅̅̅̅, different phases or ischemic
coefficient, β. For every 1 µmHg/PU increase in ∆𝑉𝑅
conditions have a different effect on the slope, β, describing the relationship between
̅̅̅̅ and ∆MPQ pain. Using Tukey-Kramer’s for post hoc comparisons, levels that do
∆𝑉𝑅
̅̅̅̅ (p ≤ 0.05).
not share a letter have different effects on ∆𝑉𝑅
Factor

p value

Level

∆MPQ Pain*Ischemia

0.0121

PECO+

Tukey
A

PECO∆MPQ Pain*Phase

<.0001

O

B
A

E

B
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Fixed Effect

Slope Effect, β
[µmHg/PU∙MPQ]

𝛽1 𝛼𝑃𝐸𝐶𝑂+

-2.81

𝛽1 𝛼𝑃𝐸𝐶𝑂−

+23.3

𝛽1 𝛼𝑂

+23.6

𝛽1 𝛼𝐸

-1.42

Appendix P: Variability in Pain associated with Paresthesia

A

B

Figure 3.13: Paresthesia and Pain Variability between Subjects. A. Significant
between-subject variability occurred in self-reported changes in MPQ pain when
paresthesia descriptors were included in the questionnaire. B. Tukey post-hoc
comparisons show that participants felt significant paresthesia with TENS treatment as
compared to placebo (T-P). Values shown as means ± SE.
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